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Abstract 
 
Proteins containing intrinsic disorder often undergo dynamic conformational 
change in response to ligand binding or post-translational modification. Chemical 
dissection of these dynamic protein perturbations presents an approach for manipulating 
the resultant functional outcomes. Translational repressor protein 4E-BP1 is an example 
of an intrinsically disordered protein (IDP) that both folds into a short a-helix upon binding 
to its protein ligand, eIF4E, and a four-stranded b-sheet upon hyperphosphorylation.  
Post-translational modifications (PTMs) are an important mode of regulation for 
IDPs and intrinsically disordered regions (IDRs); however, the enzymatic generation of 
uniformly modified proteins in vitro remains challenging. Studying PTMs in IDPs is further 
complicated by their instability and markedly dynamic nature. Chemical methods of site-
specific PTM incorporation have been developed in attempt to circumvent this problem. 
Here, we evaluate a chemical mutagenesis-based approach for generating pCys as a 
phosphomimetic in the 4E-BPs, a family of proteins that acts to repress cap-dependent 
translation, and whose function is regulated by a hierarchy of phosphorylation events. 
Using NMR and CD spectroscopy, we have characterized pCys in two unique contexts 
within 4E-BPs: induction and destabilization of secondary structure. Understanding the 
applicability of pCys in these unique contexts is important for expanding its use to answer 
biological questions in complex protein systems. 
Additionally, biophysical methods for analysis of binding-induced structural changes 
are low throughput, require large amounts of sample, or are extremely sensitive to signal 
 xiv 
interference by the ligand itself. Herein, we describe the discovery and development of a 
conditionally fluorescent 4E-BP1 peptide that reports structural changes of its helix in 
high-throughput format. This reporter peptide is based on conditional quenching of 
fluorescein by thioamides. In this case, fluorescence signal increases as the peptide 
becomes more ordered. Conversely, destabilization of the a-helix results in decreased 
fluorescence signal. The low concentration and low volume of peptide required make this 
approach amenable for high-throughput screening to discover ligands that alter peptide 
secondary structure. 
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Chapter 1 : Introduction to Protein Disorder and its Role in Cap-Dependent 
Translation 
1.1 An Introduction to Intrinsically Disordered Proteins 
 
For decades, the relationship between protein structure and function was held to 
be straightforward: the primary amino acid sequence of a protein dictates the formation 
of stable structures, that in turn, determine protein function.1 Upending that long-held 
paradigm are the more recent estimates that approximately 66% of eukaryotic proteins 
contain segments of 30 res or more that are predicted to be structurally disordered, 
termed intrinsically disordered regions (IDRs). In fact, there are proteins completely 
lacking stable structures.2 What we now know is that proteins tend to occupy three 
structural classes, termed the “protein trinity”: ordered, molten globule, and random coil 
Random Coil Molten Globule Ordered 
Figure 1.1 “The Protein Trinity Represents the Three Classes of Protein Structure”  
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(Figure 1.1).3 Intrinsically disordered proteins (IDPs) primarily exhibit the properties 
of a random coil, although they usually contain residual secondary structural elements.4 
In other words, an IDP can be thought of as an ensemble of protein populations that 
occupy structural states over a continuum of conformational space. Given that the 
majority of the human proteome consists of IDRs or IDPs,4 one question that arises is 
why this protein class was only recently uncovered. The answer to this is found by 
examination of the way proteins were historically discovered and isolated in vitro. 
Traditionally, new proteins were identified through functional screens of cell lysate, 
creating a bias for proteins that were both soluble and displayed enzymatic activity.3 
Because of this, the abundance and function of IDPs have were largely unexplored until 
the 1990’s.4 
In contrast to well-ordered proteins, IDPs do not adopt a single, stable 3D 
structure. Instead, they sample many conformations over time2. The resulting high 
flexibility of these proteins is encoded in their primary amino acid sequences. For 
example, IDP amino acid sequences are typically considered “low complexity”,5,6                                                       
containing multiple repeats of the same or similar amino acids that hinder the formation 
of a hydrophobic core.3 They are specifically deficient in structure promoting amino acids, 
such as C, W, I, Y, F, L, H, V, and N.2 Conversely, IDPs are enriched in amino acids A, 
G, R, T, S, K, Q, E, and P,2 residues that are either disrupting to secondary structure, or 
commonly targeted for enzymatic post-translational modification, a central mechanism of 
IDP regulation. 
While IDPs do not rely directly on stable structural motifs to inform their function, 
they often contain short, functional sequence repeats, that are conserved for regulatory  
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purposes,2-4 A common example of this are PEST sequences, which are short stretches 
enriched with Pro, Glu, Ser, and Thr residues. These PEST sequences appear to regulate 
protein turnover, as these sequences motifs are usually phosphorylated, priming the 
protein for ubiquitination and protein degradation.7,8 Another example of such sequences 
are protein recognition sequences that fold into secondary structures upon binding to their 
partner4. While it is not clear what the evolutionary origin of these sequence motifs are, is 
had been proposed that they may have arisen via repeat expansion.3 
Although the highly dynamic nature of IDPs, presents a unique challenge for their 
study, biophysical and bioinformatic techniques have proven extremely useful for 
understanding their functions. Computational programs have arisen as powerful tools for 
identification of IDPs. A number of bioinformatic programs like PONDR, FoldIndex, and 
GlobPlot have been developed to predict protein disorder from primary amino acid 
sequence (Table 1.1).1,3 Additionally, a number of biophysical techniques have been 
adapted to elucidate the dynamic nature of IDPs in solution, including: nuclear magnetic 
resonance (NMR) spectroscopy, circular dichroism (CD) spectroscopy, hydrodynamic 
measurements, fluorescence energy transfer (FRET) and small angle x-ray scattering 
(SAXS).3,4 Occasionally, IDPs also form conditionally rigid secondary structures that can 
be observed in x-ray crystallography experiments. 
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Table 1.1 “Bioinformatic Resources for Analysis of Protein Disorder” 
 
 
Program Description Website 
PONDR 
Uses sequence attributes like fractional amino acid 
composition, hydropathy, and sequence complexity to 
evaluate sequence disorder over windows of 9 to 21 amino 
acids. 
www.pondr.com
 
ANCHOR 
Predicts disordered regions that fold upon ligand binding, 
without information of partner proteins9 
http://prdos.hgc.jp/cgi-bin/top.cgi
 
PrDOS 
Uses a predictor that considers sequence alignment of 
homologs10 
http://anchor.enzim.hu/
 
Espritz 
Uses two binary qualifiers: one for short disordered regions 
and one for long disordered fragments11 
http://protein.bio.unipd.it/espritz/
 
D2P2 A database of disordered protein predictions12 http://d2p2.pro/
 
FoldIndex 
Analyzes the ratio of local net charge relative to 
hydropathy13 
https://fold.weizmann.ac.il/fldbin/findex
 
DisEMBL 
Predicts disordered loops, and dynamics regions missing 
from the PDB 
http://dis.embl.de
 
GlobPlot 
Considers the relative propensity of an amino acid to be in 
an ordered or disordered state 
http://globplot.embl.de
 
DISOPRED 
Uses multiple sequence attributes to train algorthm against 
the entire polypetide sequence14 
http://bioinf.cs.ucl.ac.uk/psipred/?disopred
=1
 
DISPROT A database of disordered protein regions http://www.disprot.org
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1.2 Functions of Intrinsic Disorder in Cellular Processes 
IDPs are particularly prevalent in cellular signaling pathways, where they mediate 
signal transduction through networks of protein-protein interactions (PPIs).3 Intrinsic 
disorder creates a larger surface area for ligand binding, where multiple well-ordered 
proteins would be required to make the same contacts.3  A thermodynamic consequence 
of this is the commonly observed, non-homogenous distribution of binding free energy, 
where multiple weakly binding motifs work synergistically to drive PPI formation (Figure 
1.2).4 It is often the case that, an IDP’s PPI(s) are mediated through a single, 
indispensable hot spot peptide region. While the hot spot modulates PPI formation, other 
regions function to enhance overall binding affinity.3,4 In both of the aforementioned 
cases, synergistic binding also contributes to the specificity of IDPs for the ligand.3 
Another benefit of multiple interacting motifs is that they allow for pathway crosstalk. 
Weak binding sites are highly dynamic, allowing for the IDP to interact with modifying 
enzymes or other binding partners. This property is of particular importance in signal 
Figure 1.2 “Examples of IDPs that Exhibit Non-Homogenous Distribution of Binding Free 
Energy” A) 4E-BP1 utilizes two synergistic sites for eiF4E binding B) HIF1 utilizes multiple 
synergistic sites for CBP binding 
A) 
 
B) 
 
PDB 4UED 
 
PDB 1L8C 
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transduction, as it allows for rapid dissociation after binding, enabling expeditious signal 
termination.4  
Table 1.2 “Cellular Processes Mediated via Protein Disorder” 
In addition to being critical for binding to partner proteins, hot spot regions often 
exhibit binding mediated structural polymorphism. Most commonly, IDPs fold into an a-
helical structure at the binding interface, with the overall dynamics of an IDP being 
dependent on the identity of the ligand(s) bound at a given time; the thermodynamic 
favorability of protein binding offsets the decrease in entropy that results from folding. 
IDPs are also tightly regulated by post-translational modifications (PTMs), some of which 
include methylation, acetylation, and phosphorylation. In fact, phosphorylation is a 
Cellular Process 
Disordered 
Protein 
Brief Description of Function 
Transcription NCBD (CBP) Binds coactivators for gene transcription3 
Apoptosis PUMA Binds to sequester anti-apoptotic proteins & stimulate apoptosis4 
Cell Cycle p53 Regulation at G1/S checkpoint4 
Circadian clock 
regulation 
FQR 
Regulates circadian clock of Neurospora spp. in a 
phosphorylation dependent manner4 
Liquid-liquid phase 
separation 
DYRK3 Recruits mTOR to stress granules for pathway inhibition4 
Alternative splicing Snu17p 
Regulates pre-mRNA slicing and nuclear retention as a part of the 
RES complex4 
Protein translation 4E-BP Regulates initiation of cap-dependent translation19 
 7 
critically important regulatory modification in signal transduction. Of interest, regions of 
protein disorder comprise the majority of documented phosphorylation sites.4 
Phosphorylation regulation of IDPs, serve a variety of molecular functions, acting as a 
molecular clock, a molecular rheostat, or modulating structure and conformation.4,15-18  
Given the advantages of protein disorder for cell signaling, it is found to play an important 
role in a number of cellular functions (Table 1.2). These include the cell cycle, programed 
cell death, transcription, and translation.  
 
Table 1.3 “mRNA Transcripts Regulated in a Cap-Dependent Manner” 
 
1.3 Regulation of Cap-Dependent Translation Determines Cell Growth and 
Development 
One cellular process that is heavily regulated by an IDP is cap-dependent 
translation. Within the flow of genetic information in eukaryotes, a subset of mRNA 
transcripts are regulated in a manner that is dependent upon molecular recognition of a 
mRNA transcript Cellular Function 
ornithine decarboxylase (ODC) polyamine synthesis20 
c-Myc transcription21 
VEGF angiogenesis22-24 
Bcl-2 apoptosis25 
Survivin apoptosis26 
ATP5D mitochodrial ATP synthesis27 
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methylated guanine base that caps the 5’ prime end of the mRNA transcript (Table 1.3). 
Expression of proteins that are critical for normal cell growth and development are 
specifically regulated in a dap-dependent manner. 
 
Cap-dependent translation is most tightly controlled at the initiation step, which 
requires formation of the eukaryotic initiation factor (eIF) 4F complex. The eIF4F complex 
Figure 1.3 “Cap-Dependent Translation is Regulated by the Convergence of 
Multiple Signaling Pathways onto the 4E-BP/eIF4E axis” 
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is comprised of scaffolding protein eIF4G, RNA helicase eIF4A, and the cap-binding 
protein eIF4E. Recruitment of eIF4E to the eIF4F complex by eIF4G is the rate-limiting 
step for cap-dependent translation initiation, and is regulated by a family of intrinsically 
disordered 4E-binding proteins (4E-BPs) (Figure 1.3). By sequestering eIF4E away from 
the eIF4F complex, the 4E-BPs negatively regulate cell growth,28-30 and proliferation.31 
More specifically, the 4E-BPs prevent progression of cells from G1 to S phase.26 They 
also promote apoptosis by regulating translation of antiapoptotic proteins.29 Many 
signaling pathways converge onto the eIF4E-4E-BP axis (Figure 1.3),21,26,27,32-35 and as a 
result, dysregulation of cap-dependent translation, is correlated to a number of biological 
processes and disease states (Table 1.4). Thus, understanding 4E-BP disorder and 
dynamics as a mechanism for its function unlocks the potential for discovery and 
development of biologically active chemical probes that selectively reprogram the cap-
dependent translational machinery. Directly targeting 4E-BP conformational dynamics 
could be a means by which possible chemoresistance, conferred through compensatory 
upstream signaling pathways, can be circumvented. 
 10 
Cellular 
Process/Disease 
State 
 
Correlation to Cap-Dependent 
Translation Initiation 
Aging  
Cap-dependent translation of proteins 
required for mitochondrial process 
induction36 
Diabetes  
Higher HDL is correlated to lower 4E-BP 
expression37,38 
Obesity  
Lower 4E-BP1/2 expression results in 
lower body fat and increased insulin 
resistance27,39 
Viral Infection 
Adenovirus 
Possible increased in cap-dependent 
translation for early infection32, 
Increase in p4E-BP132,40 
Rhabdovirus Decrease in p4E-BP141 
Herpesvirus 
Increase in cap-dependent translation via 
ICP6 stabilization of eIF4E-eIF4G 
interaction42,43 
Papillomavirus 
E6 dependent increase in cap-dependent 
translation44 
Neurological 
Disease 
Autism Spectrum 
Disorder 
Increased cap-dependent translation via 
decrease 4E-BP2 activity27,45 
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Alzheimer's Disease 
Increased 4E-BP2 activity is correlated to 
neuronal death46,47 
Cancer 
Breast 
Increased p4E-BP1 is associated with 
tumorogenesis25,48 
Ovarian 
Increased p4E-BP1 is associated with 
tumorogenesis and poor prognosis49 
Melanoma 
Increased p4E-BP1 is associated with 
tumorogenesis50 
Prostate 
Increased p4E-BP is associated with 
tumorogenesis51 
Pancreatic 
Increased 4E-BP1 expression; 
desensitization to mTORC1 
phosphorylation52 
Lower 4E-BP1 expression in PDAC53 
Esophageal Lower 4E-BP1 expression54 
Lung 
Increased p4E-BP1 is associated with 
tumorogenesis and poor prognosis in 
NSCLC55 
Table 1.4. “Disease States Correlated to Aberrant Cap-Dependent Translation” 
 12 
 
1.4 4E-BP Molecular Function and Regulation 
Early studies aimed at identifying new insulin responsive proteins in rat 
adipocytes56-58 lead to the discovery and identification of Phosphorylated Heat and Acid 
Stable protein regulated by Insulin (PHAS-I).59 Subsequent work provided a link between 
PHAS-I and cap-dependent translation via insulin-dependent eIF4E binding, leading to 
the protein being renamed 4E-binding protein 1 (4E-BP1).60,61 There have been a total of 
three 4E-BP isoforms identified in humans, termed 4E-BP1, 4E-BP2, and 4E-BP3.  4E-
BP molecular action involves binding eIF4E via a hotspot region that contains an eIF4E 
binding motif YXXXXFf. This motif is shared by eIF4G, which directly competes for eIF4E 
binding. The hotspot peptide alone has an eIF4E binding affinity of 50 nM, only 10-fold 
weaker than the 5 nM binding affinity of the full-length protein19. 
4E-BP function is regulated on a number of levels, from gene expression to post-
translational control. The genes encoding 4E-BPs are transcriptionally regulated by ATF4 
and SMAD4,30,62 which increase 4E-BP expression, as well as EGR1,54 which decreases 
expression,63 and c-Myc. 4E-BP1 and 4E-BP2 are the most well characterized, differing 
largely in their tissue localization. Both isoforms are ubiquitously expressed;63,64 however, 
4E-BP1 is enriched in skeletal muscle and adipose tissue,64 while 4E-BP2 is enriched in 
brain and neuronal tissue.65 Little is known about the molecular or biological function of 
4E-BP3; thus, there will not be further discussion of it here. Cellular concentration of 4E-
BPs are also regulated through protein degradation. The normal half-life for 4E-BP1 is 
reported at about 16 h. Phosphorylation within 4E-BP PEST sequences appears to 
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decrease stability in cells.7,8 4E-BP1 has also been reported to be polyubiquitinated when 
unbound to eIF4E, targeting it for proteasomal degradation.66,67 
 
Folding of a short region of 4E-BP into a short, amphipathic a-helix, a consequence 
of target binding, is regulatory feature that contributes to its eIF4E binding activity (Figure 
1.5A). This is common in IDP mediated PPIs, with other notable examples of IDPs or 
Figure 1.4 “Multiple Sequence Alignment of 4E-BP and eIF4E” A) Multiple Sequence 
Alignment of human 4E-BP isoforms; gray indicates a mTORC1 recognitions sequence, red 
indicates a canonical phosphorylation site and yellow indicates the binding induced a-helical 
region B) Comparison of the hot spot peptide regions of 4E-BP and eIF4G 
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IDRs undergoing this phenomenon including the pKID IDR that folds upon the KIX 
surface4 and p53 ordering upon MDM2 binding.3 The 4E-BP helix is in the hotspot binding 
region for eIF4E; however, 4E-BP forms a bipartite binding interface, with residues Ile78-
Thr82 forming a weak antiparallel b-interaction with eIF4E (Figure 1.2A),68,69 accounting 
for the higher eIF4E binding affinity of full-length protein relative to the hotspot 
peptide.69,70 While favorable hydrophobic interactions at the PPI interface make up some 
of the entropic cost of protein ordering, a thiol—pi interaction between Phe58 and Cys62 
of 4E-BP1 (Figure 1.5B) and a cation—pi interaction between Phe58 and Arg62 of 4E-
BP2 (Figure 1.5C), likely stabilizes the folded structure on the eIF4E surface.71 
 Post-translational modification presents another powerful means of 4E-BP 
regulation. There are 6 canonical proline-directed 4E-BP phosphorylation sites, at Thr37, 
Thr46, Ser65, Thr70, Ser85, and Ser101, with an additional phosphorylation site reported 
Binding Induced 
Folding 
Intrinsically Disordered 
Protein 
A) 
PDB 3AM7 PDB 4UED 
B) C) 
Figure 1.5 “4E-BP a-helix formation in mediated by eIF4E binding” A) A cartoon 
representation of 4E-BP helix formation on the eIF4E surface. B) a thiol-pi interaction and C) 
a cation-pi interaction appear to stabilize helices of 4E-BP1 and 4E-BP2, respectively. 
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at Ser112 of 4E-BP1.16,29,31,72-75 This is common mode of regulation for IDPs, which are 
often modulated sequentially or in specific combinations to effect function in signal 
transduction pathways.4 Phosphorylation at Thr37, Thr46, Ser65, and Thr70 directly 
effect eIF4E binding in a mammalian target of rapamycin (mTOR) complex 1 (mTORC1)-
dependent manner.32,60,61,65,72,76 Activity of mTORC1 is stimulated in response to amino 
acids, growth factors and hormones to promote cell growth and proliferation.77,78 
Substrate recognition by mTORC1 is mediated by its Raptor protein component, which 
recognizes an N-terminal RAIP motif or a C-terminal TOS sequence of 4E-BP.62,79-81 
 A hierarchal mechanism of 4E-BP phosphorylation has been proposed, where 
phosphorylation of Thr37 and Thr46 is thought to prime the protein for subsequent 
phosphorylation events.74 These two phosphoevents decrease the binding affinity of 4E-
BP by almost 90-fold.16 Structural studies indicate that this is likely due to a unique 
phosphorylation-induced folding phenomenon, where phosphorylation of these two sites, 
which are both located within a TTPGGT sequence repeat, results in partial protein folding 
into a four-stranded antiparallel b-sheet, and sequesters the eIF4E binding hot spot into 
the fold.16 Despite the large decrease in 4E-BP binding affinity, data from both cell-based 
and in vivo studies, show that this phosphostate still preferentially binds to eIF4E over 
eIF4G. In fact, it is phosphorylation of Ser65 that appears to promote preferential binding 
by eIF4G and initiation of cap-dependent translation,75,82 although there is conflicting data 
for this in brain tissue of a ischemia reperfusion stress model.47 
 Biophysical studies make a case for pSer65 as the critical phosphoevent 
abolishing eIF4E binding, as it is contained within the hot spot peptide region. While Ser65 
does not directly contribute to the 4E-BP-eIF4E interaction,69 phosphorylation at this site 
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is evidenced to destabilize helix formation upon eIF4E binding.17,18 This is a precedented 
occurrence, as phosphorylation of Ser or Thr residues C-terminal to an a-helix is well 
documented to be destabilizing to the secondary structural element.18,83 Destabilization 
of the 4E-BP helix by pSer65 is proposed to be due to an electrostatic repulsion 
mechanism, as a-helices form an electric dipole, where the C-terminal orientation of the 
backbone carbonyl oxygen atoms, create a net negative charge at the C-terminus of the 
helix. Thus, a negatively charged phosphate group, would disrupt the helix dipole. 
Intriguingly, pSer65 alone has been shown to be insufficient for loss of 4E-BP binding to 
eIF4E,75,82,84 suggesting that this PTM downstream of pThr37 and pThr46, can be most 
accurately described as a threshold response to changes in cellular concentrations of 
growth promoting hormones and nutrients. 
 Even with the abundance of studies on hyperphosphorylated 4E-BP, particularly 
as a potential cancer biomarker, little is known about the role of phosphorylation of Ser83, 
Ser101, or Ser112. The Ser83 phosphorylation site appears to function outside the 
context of the accepted hierarchy.85 In fact, asynchronous cells show very little pSer83 in 
its hyperphosphorylated population; however, nocodazole treated cells show CDK1-
dependent enrichment in pSer83 specifically during mitosis.85 In addition, pSer83 seems 
to play a specific, yet currently unelucidated role in cellular transformation that is not 
directly tied to the 4E-BP-eIF4E PPI.85 There is also evidence that Ser101 is either 
constitutively phosphorylated or, in contrast with the accepted hierarchy, is directly 
required for phosphorylation of Ser65.80 Phosphorylation of Ser112 in 4E-BP1 is the least 
understood of all phosphoevents. This site is purportedly modified by ataxia telangiectasia 
mutated (ATM) kinase in an insulin-dependent manner,86,87 linking 4E-BP1 to DNA 
 17 
damage response. At the present time, there is little known on the specific molecular 
function of pSer112, and there is ambiguity surrounding its possible effect on eIF4E 
binding80,86.  
1.5 The 4E-BP-eIF4E Axis is a Promising Target for Chemical Modulation of Cap-
Dependent Translation  
With the abundance of evidence demonstrating the correlation between initiation 
of cap-dependent translation and disease,21,22,25,26,30,39,45,49,88-94 this process is a 
promising target for chemical intervention.89,90,95-99  Particularly in cancer and neurological 
disease, there is a clear link between increased cap-dependent translation, disease 
progression and patient prognosis.26,34,45,48-50,53,54 While activity of a number of eIF4F 
components have  been shown to be sensitive to chemical modulation, for example  
eIF4A helicase95 and eIF4E cap-binding,100,101 I will focus on effectors of the 4E-BP/eIF4E 
PPI, including perturbation of the eIF4E-E-eIF4G PPI. Along these lines, the molecules 
mentioned here fall into two classes: upstream kinase-targeted compounds (Figure 1.6) 
and eIF4E PPI targeted compounds (Figure 1.7). 
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As mentioned above, 4E-BP ability to sequester eIF4E away from the translational 
machinery and inhibit cap-dependent translation is tightly controlled by mTORC1-
dependent phosphorylation. Therefore, it is advantageous to target mTOR kinase activity 
as a way of increasing the cellular concentration of hypophosphorylated 4E-BP available 
to bind eIF4E. Indeed, this has been an effective approach. The natural product 
rapamycin is an allosteric mTOR inhibitor.76,98 While rapamycin and its analogues, termed 
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rapalogs, have found success in targeting cap-dependent translation in cancer and 
metabolic disease, they have displayed limited efficacy due in part to incomplete inhibition 
of 4E-BP relative to another mTORC1 substrate, S6K.102 
In hopes of overcoming the apparent substrate selective inhibition profile of 
rapalogs, active site inhibitors of mTORC1 (mTORi) (Figure 1.6B), and dual specificity 
mTOR/PI3K inhibitors (Figure 1.6C) were developed. These inhibitors have shown 
favorable results in cancer models, as they both show more effective inhibition of 4E-BP 
phosphorylation, and also inhibit mTOR complex 2 (mTORC2), which can activate an 
AKT-dependent negative feedback loop that infers resistance to allosteric mTORC1 
inhibition.51,95,103 While showing great improvement over rapalogs, there is still evidence 
for incomplete p4E-BP inhibition, as in the case of PP242.104 This can be attributed to a 
number of factors known to cause resistance to kinase inhibitors, including active site 
mutations105 and activation of compensatory kinases.106,107 
 Another approach, which is complementary to kinase inhibition, is direct 
modulation of eIF4E interaction with eIF4G and/or 4E-BP. In this vein, peptide-based 
inhibitors such as caged peptides have been explored.101 As is the case for 4E-BP, the 
hotspot region of eIF4G is disordered, until ligand binding induces formation of an 
amphipathic helix. This has prompted the development of stapled peptides based on 
bothe eIF4G and 4E-BP peptide sequences.108,109 Hydrocarbon peptide stapling presents 
the opportunity to stabilize the bound conformation of a highly dynamic peptide, limiting 
the conformations that are sampled upon ligand binding, and improving the overall 
binding affinity by lowering the on rate,110-112 although this is not always the case.  The 
peptide stapling strategy involves synthesis of peptide containing an intramolecular 
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hydrocarbon linkage, usually replacing amino acids that are relatively dispensable for 
target binding, with i, i+4 spacing, mimicking the spacing of the backbone hydrogen 
bonding network that defines a-helicity. In addition to improvements in binding affinity 
relative to linear peptide sequences, stapled peptides have been found to increase cell 
permeability and proteolytic stability.108,109 While this has proven to hold true in a number 
of cases, peptide stapling can have a negligible effect on some systems,4,112 and have 
even been reported to upset PPI networks, as in the case of p53.4 Stapled peptides have 
been designed to mimic both eIF4G113,114 and 4E-BP114,  show modest improvements in 
eIF4E binding affinities. These data are encouraging for design of future iterations of 
conformationally restricted eIF4E binding peptides. 
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  Small molecule modulators of eIF4E PPIs have also been explored. First, was the 
discovery of 4EGI-1,99 from a fluorescence polarization based high-throughput screen. 
This compound was initially reported to inhibit eIF4G interaction, while at the same time 
promoting 4E-BP association. The discovery of 4EGI-1 undoubtedly set a precedent for 
small molecule perturbation of eIF4E PPIs; however, subsequent work revealed it to have 
an allosteric mode of action,68,115 displaying off-target inhibition of cap-independent 
protein translation.116 Two other small molecules identified through FRET based 
screening,117 4E1RCat96 and 4E2Cat,118 were later reported as inhibitors of both eIF4G 
and 4E-BP binding to eIF4G, with low micromolar affinity in in vitro assays. These 
compounds also exhibit minimal effect on cap-independent translation, although more 
work must be done to validate the long-term effects of inhibition of cap-dependent 
translation on cap-independent processes.53 
1.6 Application of Chemistry-Based Strategies for Probing 4E-BP Conformational 
Dynamics 
 With the above work in mind, there are two major contexts in which to examine 
chemical perturbation of 4E-BP activity: through modulation of its amphipathic helix and 
through chemical dissection of phosphorylation-dependent 4E-BP structural dynamics. 
Studies of  4E-BP peptide stapling have demonstrated a-helix stabilization as a promising 
approach for modulating cap-dependent translation. Building upon this work, it would be 
advantageous to identify compounds that can induce helicity of the 4E-BP helix, while still 
allowing access to eIF4E binding. In this way, the cellular concentration of 4E-BP could 
be hijacked to inhibit cap-dependent translation, independent of 4E-BP phosphorylation 
state. While there is precedent of chemical compounds that function through secondary 
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structure stabilization,119 there was previously no broadly applicable, high-throughput 
method to selectively screen for this class of compound. As a part of the work described 
here, I have developed a fluorescent peptide probe capable of doing this in the context of 
the 4E-BP helix, with the potential for application to a number of relevant systems. 
Additionally, with my collaborators at University of Toronto and the Hospital for Sick 
Children, evaluated a chemical mutagenesis approach to generation of pCys as a 
pSer/pThr phosphomimetic. This work, originally envisioned for application to elucidate 
the molecular roles of pSer83, pSer101, and pSer112, shed light on the chemical 
requirements of a potential 4E-BP phosphomimetic, as well as a number of 
considerations for development of chemical methods of PTM mimicry in complex 
biological systems.  
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Chapter 2 – A Conditionally Fluorescent Peptide Reporter of Secondary Structure 
Modulation 
*Note: This chapter contains an accepted manuscript: O.T. Johnson, T. Kaur, and Prof. 
A.L.Garner; ChemBioChem (2018) 10.1002/cbic.201800377  
2.1 Introduction  
Dynamic conformational change is a critically important mechanism of mediating 
and regulating protein function.1 From regulating the active conformation of enzymes to 
mediate catalytic turnover, to inferring selectivity in interactions between protein binding 
partners, protein structure modulation yields information about its functional 
outcome(s).1,2 Intrinsically disordered proteins (IDPs) and proteins containing intrinsically 
disordered regions (IDRs) are, by definition, highly dynamic, existing as conformational 
P 
mTORC1-dependent  
4E-BP phosphorylation 
eIF4E 
4E-BP 
Target mRNA 
eIF4G 
eIF4F complex 
eIF4E binding motif:   
YXXXXLf,  where f is M, L, or F  
Figure 2.1 “a-Helix Formation Mediates 4E-BP binding to eIF4E” 
 36 
ensembles as opposed to more ridged secondary and tertiary structures.3 Their structural 
fluidity is directly related to their function as signaling hubs in protein interaction networks 
that regulate cellular growth and development.1,2 Within these signaling cascades, 
binding-induced folding has been found to be an important aspect of the protein-protein 
interactions (PPIs) of many IDPs, affecting binding affinity and specificity.1  
An example of such structural polymorphism in ligand binding can be found in a 
family of three intrinsically disordered translational repressor proteins known as the 
eIF4E-binding proteins (4E-BPs), which regulate a subset of mRNA transcripts that are 
integral for maintenance of cellular homeostasis, including Bcl-2, ODC, and c-Myc.4-6 
These proteins function by sequestering the mRNA cap-binding protein eIF4E from 
eIF4G, which shares a similar eIF4E-binding motif, to inhibit the initiation of cap-
dependent translation (Figure 2.1).7 The 4E-BPs form a short a-helix upon binding to 
eIF4E, where helix formation is a consequence of ligand binding.1,2,7 Mechanistic target 
of rapamycin complex 1 (mTORC1)-dependent phosphorylation of 4E-BPs regulates their 
function8 in part by destabilizing this helix,9,10  suggesting that modulation of 4E-BP 
secondary structuring could be a promising strategy by which to impart functional control 
over the protein via chemical means. This rationale has been explored in the design of 
stapled peptides based on the peptide hot spot regions of 4E-BPs11 as well as their 
biological competitor, eIF4G;12 however, identifying 4E-BP helix modulators with 
specificity over the eIF4G helix  presents a challenge.  
 Traditional biophysical methods for analyzing protein and peptide structure 
include circular dichroism (CD) and Nuclear Magnetic Resonance (NMR) spectroscopies 
as well as X-ray crystallography. While these are powerful techniques that yield detailed 
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information about protein structure, they are also low-throughput, require large amounts 
of sample, and data analysis can be onerous, particularly when studying IDPs.1,2,14,15 
Thus, there is a necessity for new approaches to identify modulators of conformational 
change in a broadly applicable format. 
 
  Previous studies have demonstrated the utility of thioamides and their derivatives 
as minimally perturbing fluorescence quenchers in proteins through a photo-induced 
electron transfer (PET) mechanism.16 In contrast to other processes that result in 
quenched fluorescence through energy transfer such as fluorescence resonance energy 
transfer (FRET), PET quenching does not require spectral overlap of the electron donor Q 
fluorescence restoration fluorescence quenching 
A) 
B) 
Figure 2.2 “Rationale for Fluorescent Peptide Reporter Assay”  
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and acceptor and occurs over very short distances (~3-5 Å).17,18 Inspired by the use of 
conditional thioamide quenching for sensing protease activity17 and conformational 
dynamics of macromolecules,17,19,20 we adapted this approach to observe the disorder-
to-order transition of a 4E-BP1 hot spot peptide. Herein, we describe the serendipitous 
discovery and development of a fluorescent peptide reporter that can detect modulation 
of the 4E-BP1 helix using nanomolar peptide concentrations. 
2.2 Thiourea from FITC conjugation can meditate PET fluorescence quenching 
We initially synthesized a 15-amino acid peptide containing residues Thr50-Asn64 
of the 4E-BP1 isoform for development of a fluorescence polarization assay. This hotspot 
peptide contained the eIF4E-binding motif conjugated to fluorescein isothiocyanate 
(FITC) at the N-terminus via a two b-alanine linker. Interestingly, rather than reporting 
polarization upon binding to eIF4E, the peptide demonstrated increased fluorescence 
(data not shown). Because the thiourea motif formed upon FITC coupling (Figure 2.2A) 
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Figure 2.3 “Optimization of Fluorescent Peptide Concentration” A) Peptide relative 
fluorescence signal (RFU) (ex/em: 494/520 nm) was read to determine the minimum 
peptide concentration required to give significant fluorescence signal over assay buffer 
alone B) Fluorescence signal of 5 nM and 10 nM peptide were measured with and without 
the presence of 50% TFE, to determine which peptide concentration would give the best 
signal-to-background ratio.  
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has been shown to be quenching similar to thioamides, our hypothesis was that in a 
dynamic solution state, this moiety may be partially quenching the disordered 4E-BP1 
peptide’s fluorescence via PET. Any increase in peptide helicity (i.e. upon eIF4E binding) 
would subsequently reposition the thiourea out of the PET distance, thereby decreasing 
the effective concentration of quenched peptide and resulting in the observed increase in 
fluorescence signal (Figure 2.2B). Conversely, a decrease in fluorescence signal would 
be expected when the helix is destabilized due to an increase in the effective 
concentration of the quenched peptide. 
To explore this hypothesis, fluorescence measurements of the FITC-4E-BP1 
peptide and a FAM conjugated peptide were recorded in the presence and absence of 
50% 2,2,2-trifluoroethanol (TFE), a solvent known to induce helicity in 4E-BP1 and other 
peptides.21 First, 10 µL solutions of peptide were prepared in assay buffer pH 7.4 at 
*** 
** 
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Figure 2.4 “Determination of Thiourea-Specific Fluorescence Quenching” A) RFU (ex/em: 
494/520 nm) of 10 µL of 10 nM FITC- or FAM-conjugated 4E-BP1 peptides in Assay Buffer (50 mM 
sodium phosphate pH 7.4, 200 mM NaCl, 1 mM DTT, and 1 mM EDTA)  in the absence or presence 
of 50% TFE. FAM-conjugated peptide fluorescence does not increase in TFE to the degree of the FITC-
conjugated peptide.  
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concentrations from 1—10 nM and the signal, in relative fluorescence units (RFU) (ex/em: 
494/520 nm) was read to determine the minimum concentration required to give 
significant fluorescence signal over assay buffer alone (Figure 2.3A). Accordingly, 
solutions of 5 nM and 10 nM peptide were prepared with and without the presence of 50% 
TFE to determine which peptide concentration would give the best signal-to-background 
ratio, treating solution containing peptide and buffer with 50% TFE as signal and peptide 
in buffer alone as background (Figure 2.3B).  Based on this data, 10 nM peptide was used 
for all future fluorescence measurements.   
As shown in Figure 2.4A, a 2.5-fold increase in fluorescence was observed upon 
the addition of TFE to a 10 nM solution of the FITC-4E-BP1 peptide, which was greater 
than that observed for the FAM peptide. Importantly, using circular dichroism (CD) 
spectroscopy, we confirmed that TFE enhanced the FITC peptide’s helical propensity 
from 7% to 33% in the absence and presence of TFE, respectively (Figure 2.4B), with a 
similar increase for the FAM peptide. Notably, a C-terminal FITC-4E-BP1 peptide was 
also prepared; however, it exhibited little helical propensity even in 50% TFE (Figure 2.5). 
This finding was unsurprising, as the available structural characterizations indicated that 
C-terminal modification of the 4E-BP1 helix likely disrupts the formation or stability of the  
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Figure 2.5 “C-terminal FITC conjugation diminishes peptide helical propensity” 
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peptide helix by destabilization of the helix dipole. Together, these results offered 
preliminary substantiation for our hypothesis that the observed increase in fluorescence 
signal was linked to helix induction. 
2.3 A Thiol-Aromatic Interaction Stabilizes the 4E-BP1 a-helix 
As further proof for the mechanism of fluorescence enhancement, we probed a 
cysteine-aromatic interaction in the 4E-BP1 peptide (Cys62-Phe58; Figure 4A), which we 
hypothesized would stabilize  helical conformation.22 Consistent with our hypothesis, 
alkylation of the cysteine residue using iodoacetamide caused a 4.8-fold decrease in 
peptide fluorescence, which was not altered with 50% TFE (Figure 2.6B). Importantly, 
these results were corroborated by CD spectroscopy (Figure 2.6C). These data not only 
show the ability of our peptide reporter to detect helix disruption, but also serve as 
confirmation that the TFE-induced increase in fluorescence of the unmodified peptide is 
not due to non-specific solvent effects on fluorescein itself.  
 42 
 
Co
ntr
ol 
Pe
pti
de
Co
nto
l P
ep
tid
e +
TF
E
Al
ky
lat
ed
 Pe
pti
de
Al
ky
lat
ed
 Pe
pti
de
 +T
FE
0
5
10
15
20
200 220 240 260 280
-20000
-10000
0
10000
20000
30000
FITC
FITC + TFE
Alk
Alk + TFE
PBD: 4UED 
B) C) 
A) 
Figure 2.6 “A Thiol-Aromatic Interaction is Required for 4E-BP1 helix stabilization” A) Phe58 and 
Cys62 form a H-bond-like interaction in the 4E-BP1 helix. B RFU (ex/em: 494/520 nm) of 10 µL of 10 
nM FITC-4E-BP1 peptides in Assay Buffer in the absence or presence of 50% TFE. Alkylation of Cys62 
by iodoacetamide decreased peptide fluorescence relative to the unmodified FITC-4E-BP1 peptide. 
This decrease in RFU is unaffected by the presence of 50% TFE. C) Alkylation of Cys62 by 
iodoacetamide decreased peptide helicity relative to the unmodified FITC-4E-BP1 peptide. This 
decrease in helicity was unaffected by the presence TFE.  
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2.4 Optimization for HTS format 
To further characterize our reporter peptide and potentially improve the signal-to-
background (S/B) of our assay, we explored the effect of incorporating additional 
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Figure 2.7 “Incorporation of Additional Thioamides does not Significantly Improve 
Signal-to-Background” A) Peptide sequences of thioamide-containing peptides (circled in 
orange). B) RFU (ex/em: 494/520 nm) of 10 µL of 10 nM FITC-4E-BP1 peptides in Assay Buffer 
in the absence or presence of 50% TFE.  Signal to background ratios were determined by 
dividing the fluorescence signal of each peptide in 50% TFE by its fluorescence signal in assay 
buffer alone 
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thioamides within the peptide sequence.17,19,23 We chose to incorporate thioleucine in 
place of Leu59, which is contained within the helix, and thioisoleucine in place of Ile53, 
which is N-terminal to the helix (Figure 2.7A). Fmoc-protected thioamide amino acid 
precursors were synthesized as described17,24 and used in solid-phase peptide synthesis. 
While additional thioamides did decrease the overall fluorescence of the peptides, the 
S/B was not significantly improved (Figure 2.7B). Thus, the native FITC-4E-BP1 peptide 
reporter was determined to be optimal as it does not require the synthesis of thioamide-
containing amino acid precursors.
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Figure 2.8 “Elevated pH Improves Signal-to-Background and Dose-Dependent 
Signal Response” RFU (ex/em: 494/520 nm) of peptide in assay buffer with TFE or 
protein titrations Final well volumes for fluorescence readings were 10 µL with a final 
peptide concentration of 10 nM.. All experiments were performed in triplicate. A) MBP-
eIF4E (0-500 nM) titration at pH 7.4 exhibits low RFU signal and poor signal-to-
background (1.9);  B) MBP-eIF4E (0-500 nM) titration at pH 8.5 exhibits improvements 
in both RFU signal and signal-to-background; (4.8) C) S/B at pH 7.4 = 1.5; S/B at pH 8.5 
= 4.5 in Assay Buffer with or without TFE; D) Addition of a-synuclein (0-900 nM) to the 
peptide in Assay Buffer at pH 8.5 does not give the dose-dependent response expected 
for a specific binding interaction, indicating that observed response for MBP-eIF4E 
titrations is likely due to specific binding, as opposed to a non-specific and/or aggregation 
induced phenomena. 
 
 
RF
U 
log [MBP-eIF4E] 
 46 
To recapitulate our original observation, the FITC-labelled 4E-BP1 peptide was 
titrated with varying concentrations of MBP-eIF4E. As shown in Figure 2.8A, a dose-
dependent increase in peptide fluorescence was observed. The calculated EC50 from this 
titration experiment was 93.5 ± 3.0 nM; however, the S/B from this experiment was low. 
We predicted that since fluorescein fluorescence is pH-dependent between pH 6.8-9.0,25 
raising the pH to 8.5 would improve S/B by increasing the maximum observable signal. 
Indeed, when the titration experiment was repeated at pH 8.5, a significant increase in 
S/B was observed (Figure 2.8B). Similar results were also found with TFE (Figure 2.8C). 
Moreover, no significant change in helicity trends was noted at elevated pH by CD 
spectroscopy outside of a small decrease in maximum TFE helicity, which can be 
attributed to the increase in intermolecular disulfide formation that is favored at above pH 
8.1  (Table 2.1).  
The measured EC50 value was 65.5 + 1.4 nM, which is comparable to the reported 
Kd of 4E-BP1 peptide binding to eIF4E (50 nM by isothermal calorimetry).7 We also 
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Figure 2.9 “Assay Z-Prime in 384-well Format” RFU (ex/em: 494/520 nm) of 10 µL of 
10 nM FITC--E-BP1 peptide in Assay Buffer at pH 8.5 in the absence (negative controls) 
or presence (positive controls) of 50% TFE. 
 
Sample Number 
 47 
confirmed the specificity of the signal generation, and no fluorescence enhancement was 
observed when the peptide was titrated with a-synuclein, which is not known to bind to 
4E-BP1 (Figure 2.8D). Intriguingly, the maximum fluorescence response for eIF4E 
titration was found to be much larger than the response with 50% TFE. This is likely due 
to additional hydrophobic contacts between the amino acid side-chains of eIF4E and the 
4E-BP1 peptide N-terminus. While these interactions provide additional stabilization of 
the N-terminus, resulting in lower probability of fluorescence quenching, they are not 
directly involved in the 4E-BP1 helix. 
Finally, we tested the robustness of the FITC-4E-BP1 reporter peptide for high-
throughput screening (HTS) to discover novel inducers of the 4E-BP1 a-helix. To do so, 
we calculated Z-prime value, which statistically evaluates the dynamic range and 
standard deviation for high-throughput screening.26 This yielded a Z-prime value of 0.7 in 
a 384-well plate experiment using automated liquid handling. Importantly, assays with Z-
prime values of >0.5 are classified as excellent for HTS efforts. This shows the utility of 
such a probe for the discovery of secondary structure modulators.  
2.5 Discussion 
        In conclusion, we have developed a fluorescent 4E-BP1 peptide that can report 
both induction and stabilization of its α-helix. Additionally, we have used our 4E-BP1 
peptide to probe the thiol-aromatic interaction between Phe58 and Cys62 and its impact 
on 4E-BP1 helix stability. The prevalence of similar binding-induced folding transitions in 
biological signaling pathways indicates potential utility of a conditionally fluorescent 
peptide in systems including p27 linker ordering upon binding CDK4, p53 folding upon 
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MDM2 binding, and structuring of pKID coupled to binding of KIX.[1] Such peptides could 
be used for the discovery of novel modulators of structure and function.  
       Notably, not all IDPs form static secondary structures. Such “fuzzy complexes” 
retain varying levels of conformational restriction at the bound IDP’s interaction site.[1, 27-
28] It is likely that a reporter, such as the one we have described, would only be useful in 
a subset of these systems, dependent upon the relative conformational restriction 
occurring in the bound state of a given IDP, as well as optimization of thioamide 
placement. We look forward to application of our rationale in such systems to determine 
its applicability to studying a more diverse range of IDP PPIs.  There is also the possibility 
to utilize such an approach for more complex systems. For example, native chemical 
ligation can be used for the incorporation of a fluorophore and quenching thioamide via 
protein semi-synthesis.[29-31]  
          Finally, what we describe is an equilibrium assay for a PPI in the nanomolar range; 
however, many IDPs interact with their ligands through multiple low affinity sites.[1-2] In 
application of our approach to such interactions, for example, those in the millimolar 
range, there will be two time-dependent processes affecting the equilibrium: the binding 
kinetics of the PPI and the timescale of PET quenching.  PET quenching occurs on a 
nanosecond timescale, which presumably favors PPIs with a slower dissociation rate. 
Further exploration of PPI kinetics and the correlation to PET quenching studies are 
needed to determine the range in affinity interactions that can be reliably observed in our 
platform. With these considerations in mind, our described approach demonstrates great 
promise as a chemical biology tool for observation of protein structure perturbation in a 
high-throughput format.   
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2.6 Materials and Methods 
General chemistry methods.  
NMR spectra (1H and 13C) were recorded on a Bruker BioSpin GmbH NMR. Chemical 
shifts are reported in parts per million and referenced to TMS. Spectra were processed 
using MestReNova software. Mass spectrometry (HRMS) was performed using an Agilent 
6520, Accurate-Mass QTOF LC/MS spectrometer using ESI ionization, with less than 5 
ppm error for all HRMS analyses. RP-HPLC was performed using binary gradients of 
solvents A and B, where A is 0.1% HCO2H in water and B is 0.1% HCO2H in acetonitrile 
or 0.1% HCO2H in methanol. Analytical RP-HPLC was performed using an Agilent 1260 
Infinity HPLC equipped with a ZORBAX Eclipse SB-C18 column (4.6 × 150 mm; 5 μm) at 
a flow rate of 1 mL/min, with detection at 214 and 254 nm. Preparative RP-HPLC was 
performed using an Agilent 1260 Infinity HPLC equipped with a PrepHT SB-C18 column 
(21.2 × 150 mm; 5 μm) at a flow rate of 18.6 mL/min, with detection at 214 and 254 nm. 
In all cases, fractions were analyzed off-line using an Agilent Q-TOF HPLC-MS. Pure 
fractions were then pooled and lyophilized. 
General assay methods. Peptide fluorescence measurements were carried out on a 
SpectraMax M Series Multimode Plate Reader using excitation/emission wavelengths of 
490/520 nm with a 515 nm cutoff and 3 scans/well unless otherwise indicated. 
Fluorescence was read in Corning 3677 black round-bottom 384-well plates. 
 
Data analysis.  
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All data was analyzed using GraphPad Prism version 7.0 for Mac OS X (GraphPad 
Software, www.graphpad.com). P-values for fluorescence data were determined using 2-
way ANOVA and a 99% confidence interval. EC50 values for protein titrations of peptide 
were calculated using the “Sigmoidal Dose-Response” equation for data fitting. **** p-
value < 0.0001; *** p-value = 0.001; **p-value = 0.02 ; *p-value = not statistically 
significant. 
 
Materials.  
Fmoc-protected amino acids and Rink amide MBHA resin were purchased from P3 
Biosystems and used as received. pHA-eIF4E (Plasmid #17343) was purchased from 
Addgene (GenBank ID NM_001968). pMCSG9 vector was provided by the Center for 
Structural Biology at University of Michigan. 
Synthesis. The synthesis of α-N-Fmoc-L-thioleucine-benzotriazolide (4) was adapted 
from Shalaby et al.:17,29  
 
α-N-Fmoc-L-leucine-(N-Boc)-2-aminoanilide (2): To a solution of Fmoc-Leu-OH 
(1.7675 g, 5 mmol) in dry tetrahydrofuran (50 mL) at -10 °C, was sequentially added N-
methylmorpholine (NMM, 1.10 mL,10 mmol) and isobutyl chloroformate (0.65 mL, 5 
mmol) with stirring. The reaction mixture was stirred for 15 min at this temperature and 
followed by slow addition of N-Boc-1,2-phenylenediamine (1.0483 g, 5 mmol). The 
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Scheme 2.1 “α-N-Fmoc-L-thioleucine-benzotriazolide synthesis“ 
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reaction mixture was warmed to 25 °C and stirred overnight. Upon reaction completion 
by thin layer chromatography, the solvent was evaporated in vacuo and extracted 3´ with 
ethyl acetate (~50 mL). The combined organic layers were washed with 30 mL of brine 
and 20 mL of 5% NaHCO3 and dried over anhydrous sodium sulfate. The mixture was 
again concentrated in vacuo and the crude product was purified via silica gel column 
chromatography (eluent: 10%-40% EtOAc/petroleum hexanes) to yield a white foam 
(75%). 1H NMR (300 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.76 (d, J = 7.4 Hz, 2H), 7.58 (d, 
J = 6.4 Hz, 3H), 7.38 (d, J = 6.5 Hz, 3H), 7.28 (s, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.08 (d, J 
= 15.1 Hz, 1H), 7.01 (s, 1H), 5.61 (d, J = 7.3 Hz, 1H), 5.30 (s, 1H), 4.40 (s, 3H), 4.18 (dt, 
J = 14.7, 6.7 Hz, 2H), 1.71 (d, J = 41.2 Hz, 3H), 1.49 (s, 10H), 1.07 – 0.92 (m, 6H). HRMS 
(ESI-TOF) m/z calculated for C32H37N3O5: [M + H]+ 544.2811; observed: 544.2801. 
 
α-N-Fmoc-L-thioleucine-(N-Boc)-2-aminoanilide (3): To a solution of 2 (1.86 g, 3.42 
mmol) in THF (50 mL), Lawesson’s Reagent (1.80 g, 4.45 mmol) was added and refluxed 
at 70 °C under an argon environment for 6 h. After completion of the reaction (monitored 
with TLC), the solvent was evaporated in vacuo. The crude reaction mixture was purified 
by silica gel column chromatography (eluent: 10%-40% EtOAc/petroleum hexanes) to 
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yield 3 (1.6 g, 84% yield). 1H NMR (300 MHz, Chloroform-d) δ 9.69 (s, 1H), 7.78 (d, J = 
7.8 Hz, 3H), 7.61 (t, J = 6.5 Hz, 3H), 7.40 (dt, J = 13.8, 6.7 Hz, 3H), 7.32 (d, J = 7.5 Hz, 
2H), 7.23 – 7.16 (m, 1H), 5.63 (s, 1H), 4.75 – 4.67 (m, 1H), 4.54 (d, J = 7.8 Hz, 1H), 4.46 
(d, J = 6.9 Hz, 1H), 4.25 (t, J = 7.1 Hz, 1H), 1.81 (d, J = 21.2 Hz, 4H), 1.48 (s, 10H), 1.03 
(s, 5H). HRMS (ESI-TOF) m/z calculated for C32H37N3O4S: [M + H]+ 560.2583; observed: 
560.2570. 
 α-N-Fmoc-L-thioleucine-benzotriazolide (4): To an ice-cold solution of 3 (1.83 g, 3.27 
mmol), 25% TFA in CH2Cl2 (40 mL) was added and stirred for 2 h. After completion of the 
reaction, the solvent was removed in vacuo and dried on a high vacuum overnight. The 
resulting orange solid was treated with 20 mL of 95% glacial acetic acid and cooled to 0 
°C.  Sodium nitrite (0.3384 g, 4.90 mmol) was added in small portions over 5 min. After 
30 min, the reaction was quenched with 75 mL of ice-water. The resulting precipitate was 
collected, dried and purified via silica gel column chromatography (eluent: 10%-20% 
Figure 2.10 “1NMR of α-N-Fmoc-L-thioleucine-benzotriazolide“ 
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EtOAc/petroleum hexanes) to yield 4 as a yellow solid (0.85 g, 55% yield). 1H NMR (300 
MHz, Chloroform-d) δ 8.83 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H), 7.81 – 7.56 (m, 
6H), 7.38 (dd, J = 17.4, 7.5 Hz, 4H), 6.44 – 6.34 (m, 1H), 5.72 (d, J = 24.6 Hz, 1H), 4.56 
– 4.47 (m, 1H), 4.45 – 4.36 (m, 1H), 4.27 (d, J = 7.0 Hz, 1H), 1.99 – 1.81 (m, 2H), 1.79 – 
1.65 (m, 1H), 1.15 (d, J = 5.5 Hz, 3H), 0.99 (d, J = 6.1 Hz, 3H). HRMS (ESI-TOF) m/z 
calculated for C27H27N4O2S: [M + H]+ 471.1855; observed: 471.1821. 
 
The synthesis of α -N-Fmoc-L-thioisoleucine-benzotriazolide17,29 (8) was adapted from 
Shalaby et al.: 
 
α-N-Fmoc-L-isoleucine-(N-Boc)-2-aminoanilide (6): Same as for α-N-Fmoc-L-leucine-
(N-Boc)-2-aminoanilide. White foam (85%).  1H NMR (300 MHz, Chloroform-d) δ 1H NMR 
(300 MHz, Chloroform-d) δ 8.57 (s, 1H), 7.76 (d, J = 7.4 Hz, 2H), 7.57 (d, J = 6.2 Hz, 2H), 
7.49 (d, J = 7.8 Hz, 1H), 7.39 (s, 3H), 7.26 – 7.07 (m, 3H), 7.01 (s, 1H), 5.62 (d, J = 8.7 
Hz, 1H), 4.54 – 4.35 (m, 2H), 4.23 (d, J = 6.2 Hz, 2H), 1.48 (s, 9H), 1.09 – 0.98 (m, 4H), 
0.98 – 0.88 (m, 4H). HRMS (ESI-TOF) m/z calculated for C32H37N3O5: [M + H]+ 544.2811; 
observed: 544.2831. 
α-N-Fmoc-L-thioisoleucine-(N-Boc)-2-aminoanilide (7): Same as for α-N-Fmoc-L-
thioleucine-(N-Boc)-2-aminoanilide. Yellowish foam (75%). 1H NMR (300 MHz, 
Chloroform-d) δ 7.78 (d, J = 7.3 Hz, 3H), 7.59 (d, J = 6.3 Hz, 3H), 7.46 – 7.30 (m, 4H), 
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Scheme 2.2. “α-N-Fmoc-L-thioisoleucine-benzotriazolide synthesis“ 
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7.20 (d, J = 7.6 Hz, 1H), 4.44 (d, J = 3.5 Hz, 2H), 4.26 (d, J = 6.6 Hz, 1H), 1.48 (s, 9H), 
1.11 – 0.90 (m, 6H). HRMS (ESI-TOF) m/z calculated for C32H37N3O4S: [M + H]+ 
560.2583; observed: 560.2575.  
α-N-Fmoc-L-thioisoleucine-benzotriazolide (8).  Same as for α-N-Fmoc-L-thioleucine-
benzotriazolide. Yellow solid (50%). 1H NMR (300 MHz, Chloroform-d) δ 8.85 (d, J = 8.3 
Hz, 1H), 8.21 (d, J = 7.9 Hz, 1H), 7.88 – 7.54 (m, 7H), 7.47 – 7.30 (m, 4H), 6.32 – 6.18 
(m, 1H), 5.81 (d, J = 9.9 Hz, 1H), 4.35 (dt, J = 55.0, 6.7 Hz, 4H), 2.14 (s, 1H), 1.92 – 1.60 
(m, 2H), 1.13 – 0.75 (m, 7H). HRMS (ESI-TOF) m/z calculated for C27H26N4O2S: [M + 
Na]+ 493.1674; observed: 493.1640.  
 
 
 
Figure 2.11 “1NMR of α-N-Fmoc-L-thioisoleucine-benzotriazolide“ 
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Peptide Synthesis.   
FITC-4E-BP1 peptide sequences without additional thioamides were synthesized 
on a Liberty Blue peptide synthesizer on 0.1-mmol scale using Rink Amide resin. All 
amino acid coupling reactions were performed using 5 excess equivalents of Fmoc-AA-
OH with 1:1:1 of AA:DIC:Oxyma in DMF for 4 min at 90°C for all amino acids.  Fmoc 
deprotections was performed for 1 min at 90°C in 20% piperidine in DMF. FITC was 
coupled to the unprotected N-terminus using a previously reported method.30 
FITC-4E-BP1 peptide sequences containing additional thioamides were 
synthesized manually in a 20-mL fritted syringe using MBHA Rink resin. After the initial 
deprotection in 20% piperidine in DMF, the peptide was synthesized using standard 
SPPS procedures with HBTU/DIPEA activation. For coupling of thioamide-containing 
amino acid precursors, 3.5 equiv of the amino acid was dissolved in a minimal volume 
(~2 mL) of dry DCM with 10 equiv of DIPEA17,24. Thioamide amino acid couplings were 
carried out for 2 h and repeated for a total of 3 couplings before checking thioamide 
addition to the peptide by a TFA test cleavage and mass spectrometry. After confirmation 
of thioamide incorporation, Fmoc was removed using 2% DBU in DMF to reduce side 
products24.  FITC was coupled to the unprotected N-terminus using a previously reported 
method.30 All peptides were cleaved from the resin by agitation in a 90:0.4:0.4:0.2 by 
volume solution of TFA:thioanisole:TIPS:H2O for 4 h at 25 °C. The cleaved peptide in TFA 
solution was then precipitated in ice-cold diethyl ether, and the precipitate was 
centrifuged, dissolved, and purified via RP-HPLC.  
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Protein Expression and Purification.14,15  
Human eIF4E cDNA was cloned into a pMCSG9 from pHA-eIF4E via LIC cloning 
for expression of an MBP-tagged eIF4E protein. MBP-eIF4E plasmid was transformed 
into Rosetta  cells using a standard transformation protocol. Single colonies were picked 
to inoculate 6 ´  6 mL overnight cultures in LB media containing 50 mg/mL ampicillin (amp) 
that were incubated shaking at 37 °C.  Overnight cultures were used to inoculated 1 L of 
LB media containing 50 mg/mL amp, and that culture was grown to an OD600 of 0.6. At 
this stage, the culture was induced with 1 mM IPTG and incubated shaking at 16 °C for 
16 h. Cells were pelleted by centrifugation at 6000´ g for 15 min at 25 °C, re-suspended 
in lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl, 1 mM PMSF, 1 mM EDTA, 2 mM DTT), 
and lysed by sonication. Lysate was then clarified by centrifugation at 16,000´ g for 20 
min at 4 °C. Clarified lysate was incubated 15 min on Ni-NTA resin in a Bio-Rad column, 
then the flow-through was collected. The Ni-NTA resin was washed 3 ´ with 10 column 
volumes of wash buffer (50 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 2 mM DTT), and 
eluted with the same buffer containing a gradient of 0-500 nM imidazole. The protein was 
dialyzed 3 ´ against 2 L of storage buffer (50 mM Sodium Phosphate pH 7.4, 200 mM 
NaCl, 1 mM EDTA, 2 mM DTT, 15% glycerol), distributed into 15-mL aliquots, and flash 
frozen until use. Before using protein for experiments, aliquots were thawed on ice, 
concentrated to 5 mL, purified by size-exclusion chromatography (SEC) to remove 
aggregates, and concentrated as needed, with concentration monitored by A280. Purified 
protein was stored at 4 °C for up to 5 days after SEC, after which it was discarded. 
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Circular Dichroism (CD) Spectroscopy.  
Peptides, which were dissolved as 1 mM stocks in 50 mM Sodium Phosphate pH 
7.4 or 8.5 and 30% acetonitrile, were diluted to 100-150 µM with additional phosphate 
buffer or phosphate buffer with TFE for a final TFE concentration of 50%. CD 
measurements were carried out on a JASCO J-1500 CD spectrophotometer. Baseline 
measurements were conducted using 50 mM Sodium Phosphate pH 7.4 or 8.5 and 3% 
acetonitrile. 50% TFE was added to the baseline solution for peptide measurements in 
TFE. The baseline was automatically subtracted by the Jasco software. CD spectra for 
the peptides were measured from 190-260 nm over 3 scans. Helicity was determined by 
molar ellipticity of each peptide at 222 nm using the equations below31.  
 
Equation 1: 
 
Equation 2: 
 
 
Equation 3: 
 
 
Where,  
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%H = percent a-helix content 
[q]obs222= observed molar ellipticity at 222 nm 
[q]C= Random coil molar ellipticity 
[q]¥222= Infinite  molar a-helix molar ellipticity 
T = temperature in degrees Celsius 
k = finite length correction 
Np = Number of peptide units 
  
 
 
Peptide % helicity TFE Buffer pH 
N-Term FITC 7 - 7.4 
N-Term FITC 33 + 7.4 
C-Term FITC -3 - 7.4 
C-Term FITC 7 + 7.4 
N-Term FITC 
Cys-alkylated 
3 - 7.4 
N-Term FITC 
Cys-alkylated 
5 + 7.4 
N-Term FITC 6 - 8.5 
N-Term FITC 17 + 8.5 
N-Term FITC 
Cys-alkylated 
5 - 8.5 
N-Term FITC 
Cys-alkylated 
8 + 8.5 
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Table 2.1 “Peptide Helicity from CD Experiments” 
 
Peptide Fluorescence Measurements.  
Peptides, which were dissolved as 1 mM stocks in Assay Buffer (50 mM Sodium 
Phosphate pH 7.4 or 8.5, 200 mM NaCl, 1mM DTT, 1mM EDTA) and 30% DMF, were 
diluted to appropriate working concentrations for subsequent experiments. For 
fluorescence measurements, peptides were diluted to 20 nM working solutions with buffer 
A. For TFE experiments, the working solutions were further diluted to 10 nM using either 
buffer A or TFE. To each well, 10 µL of the 10 nM peptide working solution was added, 
and the fluorescence was read immediately using excitation/emission wavelengths of 
490/520 nm with a 515 nm cutoff and 3 scans per well. For MBP-eIF4E and a-synuclein 
titrations, 10 µL of the working solution was titrated serially with 10 µL of the protein 
solutions for a final peptide concentration of 10 nM, and final protein concentrations of 
0-500 nM and 0-900 nM for MBP-eIF4E and a-synuclein, respectively. All conditions 
were measured in triplicate. 
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Chapter 3 – Biophysical Evaluation of Chemically Generated pCys as a 
Phosphomimetic for Studying Phosphorylation-Dependent Protein 
Conformational Dynamics 
*Note: The work in this chapter was carried out as part of a collaboration with Asst. Prof. Alaji Bah 
and Prof. Julie Forman-Kay at University of Toronto and the Toronto Hospital for Sick Children. 
Protein NMR Experiments were carried out by A. Bah. All other work described was carried out 
by the author (O.T. Johnson).  
3.1 Introduction 
Intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) 
are protein components of the cellular machinery that are highly dynamic in conformation 
and play an integral role in many biological events. They often serve as signaling hubs in 
protein-interaction networks and modulate processes including the cell cycle, 
transcription, and translation.1,2 Consequently, IDPs/IDRs are critical to understanding 
human pathology, as they are often dysregulated in cancer, metabolic, and neurological 
diseases.2  IDRs and IDPs are often regulated at a post-translational level.1,2 Post-
translational modifications (PTMs), namely phosphorylation at serine (Ser) and threonine 
(Thr) residues, can modulate IDP function in a manner that is additive, combinatorial, or 
a sequential,2 yielding intricate networks of post-expression protein regulation. Studying 
these phosphorylation events, both in isolation and combination, can yield a great deal of 
insight into IDPs and their role in disease; however, this can be a challenging undertaking.  
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In vitro phosphorylation of IDPs by kinases has provided information on both hierarchal 
and additive phosphorylation events where the appropriate kinase is known. In contrast, 
when there is ambiguity in the identity of the biologically relevant kinase, or the goal is to 
understand the individual function or contribution of a single phosphoevent to a larger, 
hierarchal context, in vitro kinase phosphorylation methods can become complicated and 
labor intensive. This issue has prompted the exploration and development of 
phosphomimetics. While site-directed mutagenesis to introduce aspartate (Asp) and 
glutamate (Glu) as mimics of serine and threonine phosphorylation, respectively, has 
been successful in many systems, the differences in charge, pKa, and geometry of these 
amino acids limit their suitability in many protein systems.  Thus, developing tools to 
effectively and selectively study PTMs is of particular importance to studies aimed at 
elucidating IDP and IDR function and regulation. 
 
For decades, chemists have undertaken the challenge of developing chemical 
tools to answer biological questions via site-specific expansion of amino acid side-chain 
diversity. Chemical techniques, including unnatural amino acid incorporation via amber 
codon suppression3,4 and native chemical ligation (NCL),5,6  have provided a powerful 
means of introducing non-canonical amino acids, including PTM mimics;7-10 however, 
limited success of phosphomimetic incorporation,11,12 poor protein yields, and 
incompatibility of the phosphomimetic with many required subsequent chemistries13 limit 
the application of such approaches.
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Chemical mutagenesis methodology that site-specifically targets a canonical 
amino acid can provide easy access to the post-translational expansion of amino acid 
side-chain diversity in vitro. Recently, the laboratory of Ben Davis has built upon the work 
of Koshland and others,14-18 by using  cysteine (Cys)  residues as substrates for 
conversion to the reactive Michael-acceptor, dehydroalanine (Dha).19,20 Cys occurs in low 
abundance in proteins, and when present, typically participates in disulfide bonds, limiting 
non-specific reactivity with native Cys residues in a given protein. This work, branded as 
a “tag-and-modify” approach combines site-directed mutagenesis of the desired pSer or 
pThr residue to Cys, and a bis-alkylation elimination reaction to obtain Dha (Scheme 
3.1).19,21 After generation of Dha, the protein is treated with sodium thiophosphate to 
N
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Scheme 3.1 “Chemical conversion of Cys to pCys using ‘tag-and-modify’ approach” 
 71 
generate a pCys residue (Scheme  3.1). Thus, we were inspired to adapt this 
methodology in an attempt to study a multiply phosphorylated IDP.   
4E-BPs are a family of three intrinsically disordered translational repressor 
proteins. Studies of the predominate isoforms, 4E-BP1 and 4E-BP2, have shown that the 
4E-BPs act by outcompeting scaffolding protein eIF4G for binding the mRNA cap-binding 
protein eIF4E, thus sequestering it away from the eIF4F translational initiation complex 
and inhibiting cap-dependent translation. Control of 4E-BP function is regulated by 
mTORC1-dependent phosphorylation,22,23 with the hyperphosphorylated state having a 
significantly lower eIF4E binding affinity relative to the hypophosphorylated state, causing 
the 4E-BPs to be out-competed by eIF4G, and cap-dependent translation to be 
initiated.24-26 Much of the work regarding 4E-BP phosphorylation has focus on four of the 
six canonical p4E-BP sites, Thr37, Thr46, Ser65, Thr70. However, there is conflicting 
Figure 3.1 “Structural Outcomes of 4E-BP Phosphorylation” 
 72 
data on the hierarchal phosphorylation of these sites.27,28 There is also ambiguity on the 
possible function(s) of the C-terminal phosphosites Ser83 and Ser101.  
Work by Bah and colleagues demonstrated that phosphorylation at Thr37 and 
Thr46 induces formation of two identical β-hairpins that are stabilized by hydrogen 
bonding interactions between the phosphate moiety and the amide backbone of nearby 
glycine residues in the 4E-BP2 TPGGT motifs, where these phosphosites are 
contained.29  These hairpins order 4E-BP2 residues Thr19-Arg62 into a 4 stranded 
antiparallel b-sheet, a structure that sequesters the eIF4E binding “hot-spot” region when 
unbound to eIF4E, thereby reducing its binding affinity. Their findings also provide a 
structurally informed explanation for the observation that Asp or Glu mutations are 
ineffective phosphomimetics at these positions in 4E-BPs.29,30 While the structural 
consequence of phosphorylation at Thr37 and Thr46 is critical for regulation of 4E-BP 
function, a subsequent phosphorylation event at Ser65 is what abrogates the PPI.28,31 In 
fact this PTM, positioned immediately C-terminal to a short a-helix formed at the eIF4E 
binding interface, results in destabilization of the a-helix. This occurrence is at least in 
part driven by electrostatic repulsion.31 Given the precise and opposing roles of the 
aforementioned phosphosphorylation events, we felt that 4E-BP1/2 to be an ideal system 
to test the applicability of pCys as a true phosphomimetic. Thus, in the context of these 
opposing structural outcomes in a highly dynamic IDP, we have evaluated pCys as a 
Ser/Thr phosphomimetic, using circular dichroism (CD) spectroscopy and nuclear 
magnetic resonance (NMR) spectroscopy to assess its structural outcomes. 
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3.2 The “tag-and-modify” approach is a proximity sensitive method for multiple 
Dha conversions on 4E-BPs 
 We expressed a 13C15N-labelled 4E-BP1 T37C/T46C mutant, with the two Cys in 
the wildtype sequence were mutated to Ala, in an attempt to recapitulate the entire 
phosphorylation induced 4E-BP β-fold using pCys. Treatment of the protein with 2,5-
dibromohexanediamide (DBHDA) yielded a population of protein that had undergone 
complete elimination to Dha and a population of protein that was doubly alkylated by the 
reagent as determined by mass spectrometry (Figures 3.2A and 3.2C). This is likely due 
to the close proximity of Cys37 and Cys46, as Dha modification of both Cys residues in 
the wild-type 4E-BP1 sequence was obtained in preliminary experiments (Figure 2B). 
Efforts to separate the two populations by various chromatographic methods were 
unsuccessful (data not shown), leading us to focus on an individual pCys37 modification, 
which was easier to obtain  and isolate using chemical mutagenesis (Figure 3.3). While 
this single phosphorylation site is not able to induce the full 4E-BP β-fold,  as singly 
phosphorylated Thr37 of 4E-BP does induce a single, observable hairpin and partial 
protein ordering.29 
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A) 
B) 
BrBrH2N NH2
O O
65% 
SH SH
S SH2N NH2
O O
35% 
C) 
Figure 3.2 “Conversion of Cys to Dha in systems with multiple Cys is proximity 
dependent” A) 15N13C-labelled T37C/T46C 4E-BP1 mutant showed about 65% 
conversion to the desired Dha product upon treatment with 150 eq. DBHDA. The remaining 
35% appears to form an dialkylation product where 1 molecule of DBHDA alkylates both 
cysteines of a single 4E-BP1 molecule, thus forming a covalent linkage between them; B) 
In wt4E-BP1, two Cys residues (Cys7 and Cys62) in the native sequence are fully 
converted to Dha, without any apparent dialkylation product 
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A) 
B) 
C) 
Figure 3.3 “Chemical conversion of the 15N13C-labelled T37C 4E-BP1 mutant” A) to Dha; 
B) and subsequently pCys C), as monitored by QTOF mass-spectrometry 
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3.3 pCys37 is not sufficient for induction of b-hairpin structure in 4E-BPs.  
After expression and purification of 13C15N-labelled 4E-BP1, the pure protein was 
phosphorylated by the proline-directed kinase MAPK in vitro, and the reaction was 
monitored by mass spectrometry to ensure phosphorylation of at least the two sites 
required for hairpin formation, Thr37 and Thr46 (Figure 3.4). The six canonical 4E-BP1 
phosphorylation sites and an additional Thr-Pro motif that can be recognized as a 
substrate by MAPK at the N-terminus of the protein sequence. Most of the protein appears 
to have been phosphorylated at 5 or 6 sites, indicating phosphorylation at bona fide sites, 
with a small population having apparent phosphorylation of the N-terminal Thr10, as well 
as another population of protein that is only phosphorylated at 4 sites. This protein was 
then purified to remove residual kinase, and used as a mixture of phosphostates. Having 
access to the p4E-BP2 data from Bah et al. for direct comparison of HSQC spectra,29 we 
determined such a mixture was indeed sufficient to see hairpin formation and peak 
dispersion from protein ordering. 
Figure 3.4 “Phosphorylation of 15N13C-labeled 4E-BP1 by the proline-directed kinase 
MAPK as monitored by QTOF mass spectrometry” 
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As expected, the wildtype 4E-BP1 does in fact undergo phosphorylation-induced 
secondary structuring, as demonstrated by the characteristic downfield Gly backbone 
proton chemical shifts for the two b hairpins at 11 ppm and the broader peak dispersion 
in the 1H15N HSQC NMR spectra (Figure 3.5A). At this point, we were optimistic that pCys 
could induce 4E-BP hairpin formation, as its incorportation in lieu of pThr180 of p38α 
kinase has been used to stimulate its enzymatic activity, an event that requires 
conformational restriction of the loop containing the phosphoylated residue, although this 
work was not followed up with structural studies.32  After chemical modification and 
purification to obtain Thr37pCys 4E-BP1, we performed 1H15N HSQC NMR to 
characterize the effect of pCys37 on 4E-BP1 backbone chemical shifts. Intriguingly, our 
wt 4E-BP1 
wt p4E-BP1 
pCys 37 4E-BP1 
A) 
B) 
Figure 3.5 “HSQC NMR spectra of 4E-BP1” Protein NMR samples were all at 
concentrations of 100-300 µM in 30 mM Na2HPO4, 100 mM NaCl, 1 mM EDTA, 10% 
D2O v/v, pH 6.0. A) Phosphorylated wt-4E-BP1 (red) overlayed  with  unphosphorylated 
4E-BP1 (blue);  B) pCys37 4E-BP1. The absence of a downfield glycine chemical shift 
indicates lack of hairpin formation by pCys. 
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data showed that pCys is not sufficient to induce hairpin formation in the context of 4E-
BP1 (Figure 3.5B).  
3.4 pCys as an apparent destabilizer of 4E-BP α-helicity  
Phosphorylation of a Ser or Thr residue C-terminal to an a-helix is a PTM known 
to disrupt the helix dipole through electrostatic repulsion between the negatively charge 
phosphate moiety and the net negative charge at the C-terminal end of the a-helix 
dipole.33,34 In the 4E-BPs, phosphorylation of Ser65 is indeed a helix destabilizing 
modification that critically weakens its affinity for eIF4E binding.31 The ability of pCys to 
destabilize the 4E-BP helix relative to pThr or pSer was examined by CD spectroscopy, 
using 4E-BP-derived peptides containing residues Arg51-Val67 of 4E-BP1 or 4E-BP2, 
which contains the eIF4E-binding hot spot region. Peptides were prepared using standard 
solid phase peptide synthesis to generate the native peptide sequence, and peptides 
substituting the native Ser65 with pSer, pThr. It proved difficult to obtain full conversion 
to a pure pCys-containing peptide, due to observed chemical modification of Cys62, 
despite the -StBu protecting group (Figure 3.6). As a result of these complications, we 
decided to instead study pCys65 in the context of 4E-BP2 peptides. 4E-BP2 undergoes 
the same order-to-disorder transition in response to phosphorylation at Ser65, and 
contains an Arg residue in the place of the 4E-BP1 Cys62. While this did abrogate the 
need to consider non-specific Cys modification, 4E-BP2 peptides presented another 
chemical challenge; after some amount of the desired pCys product is formed, the 
thiophosphate nucleophile is postured to participate in two competing reactions: 
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nucleophilic addition to the remaining Dha, or nucleophilic substitution at the pCys 
phosphorous atom (Scheme 3.2). 
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Figure 3.6 “Mass spectrometry data for attempts at pCys generation at Cys65Dha of a 4E-
BP1 based peptide that was protected at Cys62 by an -StBu protecting group”   
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Interestingly, in the case of the 4E-BP2 based peptide, the latter reaction appears 
to be favored. Attempts at purification, proved difficult, largely due to the limited stability 
of pCys under chromatographic conditions (data not shown). We attempted to circumvent 
this by monitoring pCys conversion to the maximum relative ratio of pCys to Dha peptide 
before nucleophilic substitution becomes favored by mass spectrometry. This yielded an 
estimated 1:1 ratio of pCys to Dha substituted peptides. 
2,2,2-Trifluoroethanol (TFE) is a solvent known to induce helicity in peptides and 
proteins by promoting favorability of the required backbone hydrogen bonding 
networks.35,36 By doing CD experiments in 50% TFE, the destabilization of maximum 
peptide helicity was examined. CD data for 4E-BP2 peptides show the expected result of 
decreased maximum α-helicity of phosphopeptides relative to the native sequence in 
TFE. Notably, the pCys65 containing peptide appears to be between 68% and 90% less 
helical than the Ser65 peptide and between 33% and 50% less helical than the pSer65 
peptide; however, the mixture of pCys-Dha, along with other apparent peptide impurities 
limit the ability to draw a simple conclusion on pCys specific helix destabilization. Because 
the estimated ratio of Dha to pCys peptide was 1:1, as determined by mass spectrometry, 
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Scheme 3.2 “Nucleophilic Addition of Sodium Thiophosphate to pCys can Occur 
Before Complete pCys Conversion 
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this lead us to consider CD measurements using a solution of pSer peptide with Dha 
peptide at a 1:1 ratio for direct comparison. 
 
Table 3.1 “Percent Helicity of 4E-BP2 S65 Substituted Peptides by CD 
Spectroscopy” 
pSer was chosen over other peptides for such a comparison, as we wished to 
assess the effectiveness of helix destabilization by pCys relative to pSer. If the mixed 
pCys sample gave CD spectra that was equal to, or less than the helicity of the pSer-Dha 
Sample Percent Helicity 
Ser in TFE 19% 
pSer in TFE 12% 
pThr in TFE 11% 
pCys in TFE 
(*pCys mix) 
6% (*2%) 
Dha in TFE 10% 
pSer mix in TFE 10% 
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Figure 3.7 “CD spectra for 4E-BP2 based peptides” All peptide CD data was collected at 
250 μM peptide concentrations in 50 mM Sodium Phosphate pH 7.4 and 15% acetonitrile, 
supplemented with 50% TFE. A) Comparison of phosphopeptides on helicity relative to the 
native sequence pCys molar ellipticity values were calculated from the difference of Dha and 
pCys-Dha mixture molar ellipticities; B) Comparison of pCys-Dha mixed solution helicity relative 
to both a pSer-Dha mixture, and Dha alone. No Dha subtraction was done for these spectra. 
(nm) 
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peptide mixture, we could more confidently propose that pCys itself is helix destabilizing. 
Conversely, if the CD spectra appeared more helical than pSer-Dha peptide mixture, 
further characterization would be necessary to make any conclusion. As shown in Figure 
3.7B, the pCys-Dha peptide mixture is at least two-fold less helical than the pSer-Dha 
peptide mixture. This observation is likely due to the contribution of pCys or possibly other 
peptide impurity, as Dha peptide alone displays a higher maximum helicity than that of 
either mixture. While it is encouraging that pCys appears to be effective in the context of 
4E-BP helix disruption, even relative to pSer, more work must be done to obtain definitive 
characterization of this modification. 
3.5 Discussion 
In conclusion, we have presented a structural biology evaluation of the “tag-and-
modify” generation of pCys in the context of IDP structural modulation. While this 
approach does require system specific considerations, it does exhibit the potential for 
broad use by any group looking to study phosphorylation by means not completely 
dependent on kinase activity. The broader utility of the current “tag-and-modify” approach 
appears to be limited by the biological or structural context in which a given PTM occurs. 
The inability of pCys to induce hairpin formation can be attributed to a number of 
differences in chemical environment. First, pCys lacks the g-methyl group possessed by 
pThr, allowing for additional rotation around that bond. Yet, while studies from the 
Forman-Kay Lab corroborate the importance of the pThr g-methyl for hairpin stability, a 
phosphorylated T37S,T46S 4E-BP2 mutant, shows that pSer can, in fact induce b-hairpin 
formation, albeit a less stable structure, as demonstrated by the upfield change in proton 
chemical shift of the hairpin Gly amide protons from 11 ppm in the case of pThr, to 10.5 
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 ppm in the case of pSer of 4E-BP2.29   
The larger Van der Waals radius of the sulfur atom is likely a major factor 
influencing the effectiveness pCys as a phosphomimetic. In addition to the resulting 
increased C-S and P-S bond lengths (~1.8 Å  and 2.1 Å respectively) relative to C-O and 
P-O bond length (~1.5 Å and 1.6 Å respectively)37 from the larger Van der Waals radius 
of sulfur compared to that of oxygen, there is also an increase in Van der Waals strain 
within the local structural environment of the 4E-BP hairpin (Figure 3.8A). The increase 
in strain is such that the most sterically favorable pCys rotamer is, in fact, predicted to 
adopt a conformation that is unable to make the necessary contacts for hairpin formation 
pThr pSer pCys 
pCys rotamer 1 pCys rotamer 2 
A) 
B) 
Figure 3.8 “Mutation of the phosphorylated residue to Ser or Cys in PyMol” A) In 
the conformation required for hairpin formation, pCys makes many unfavorable steric 
clashes compared to pThr and pSer, as visually depicted by red disks; B) The most 
sterically favorable rotamer (pCys rotamer 2) places that phosphate oxygens at an 
unfavorable distance for making the necessary contacts for hairpin formation 
 84 
(Figure 3.8B). Thus, those considering using pCys as a phosphomimetic will benefit 
greatly from a preliminary assessment of tolerance for the larger sulfur atom in a given 
protein’s local environment. 
In the case of helix destabilization, Cys has been described in some literature as 
somewhat destabilizing at the C-terminus of α-helices,38,39 exhibiting an inherent helical 
propensity that is lower than those of both Ser and Thr,39 although this observation likely 
depends on the local environment of a given helix.40-43 Thus, it is reasonable to deduce 
that the more polarizable sulfur atom itself plays a role in destabilizing the 4E-BP helix, 
by increasing the entropic cost of helix formation. In addition, evaluation of this data must 
consider the method for converting Cys to pCys. This conversion is obtained through a 
Dha intermediate, which results in a loss of chirality. After the addition of sodium 
thiophosphate, the resultant pCys residue exists in an average ratio of 3:2 of L- and D- 
conformers respectively.32,44 Precise stereochemistry is crucial to protein folding, and is 
of particular importance when considering the structural regulation of an IDP. The 
naturally occurring L- conformer is the conformer that is biologically relative, with the 
mixture of L- and D- pCys lowering the effective concentration of the relevant pCys 
conformer.  There is also evidence that the local environment influences the efficiency of 
conversions of Cys to Dha, and Dha to pCys,32 which may explain the difficulties in 
obtaining full conversion in at residue 65 of the 4E-BP peptides, as these difficulties were 
not observed when the chemistry was applied at the singular position 37 of 4E-BP1.  
Development of an approach that generates a stereospecific phosphomimetic will 
vastly expand the applicability of chemical mutagenesis to biological contexts that have 
been historically difficult to study. There has already been work toward this by Bertran-
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Vincente et al., although the yield and solvent requirements of their published method are 
not amenable to modification of most proteins.45  Radical addition to Dha, as developed 
by the Davis Lab, is another method of chemical phosphomimetic generation. The radical 
chemistry would likely overcome many steric limitations, as a C-C bond is formed in lieu 
of a C-S bond, and also presents the potential to infer stereospecificity through hydrogen 
introduction at the α-carbon; however, this chemistry is extremely oxygen sensitive, with 
no currently published method for such modifications outside of a glovebox, limiting the 
scope of its practical application. Additionally, the iodophosphonates required for the 
radical addition of the phosphomimetic to Dha are not commercially available, further 
restricting application of this methodology. A future study aimed at defining the physical-
chemical properties that directly influence pCys chemistry would be an impactful and 
exciting next step for continuing this work, and broadening the use of pCys in biophysical 
and biochemical studies.  
3.6 Materials and Methods 
General chemistry methods 
NMR spectra for small molecules (1H) were recorded on a Bruker BioSpin GmbH NMR. 
Chemical shifts are reported in parts per million and referenced to TMS. Spectra were 
processed using MestReNova software. Mass spectrometry (HRMS) was performed 
using an Agilent 6520, Accurate-Mass QTOF LC/MS spectrometer using ESI ionization, 
with less than 5 ppm error for all HRMS analyses. RP-HPLC was performed using binary 
gradients of solvents A and B, where A is 0.1% HCO2H in water and B is 0.1% HCO2H in 
acetonitrile or 0.1% HCO2H in methanol. Preparative RP-HPLC was performed using an 
Agilent 1260 Infinity HPLC equipped with a PrepHT SB-C18 column (21.2 × 150 mm; 5 
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μm) at a flow rate of 18.6 mL/min, with detection at 214 and 254 nm. In all cases, fractions 
were analyzed off-line using an Agilent Q-TOF HPLC-MS. Pure fractions were then 
pooled and lyophilized. 
2,5-dibromodiamide synthesis (DBDHA) 
 
 
Synthesis of 2,5-dibromohexaneamide from adipic acid was performed as 
previously described32. Briefly, adipic acid (10.00 g, 68.4 mmol, 1.0 equiv.) was 
suspended in thionyl chloride (30 mL, 414 mmol, 6.0 equiv.) and the mixture heated under 
reflux at 80°C under a steady stream of N2. After all the adipic acid had dissolved, the 
reaction was refluxed for an additional 1.5 h, after which the mixture was returned to room 
temperature and diluted with carbon tetrachloride (40 mL). N-bromosuccinimide (24.27 g, 
136 mmol, 2.0 equiv.) and conc. HBr (4 drops of a 42% solution in H2O) were 
subsequently added and the reaction was further refluxed at 80°C for 2 h. The reaction 
solution was then lower to 0°C for 30 min before being filtered and washed with Et2O (40 
mL). The filtrate concentrated in vacuo to give 2,5-dibromoadipoyl dichloride (1) as a dark 
red oil. The product was immediately used for the next reaction without characterization 
or purification. 1H-NMR values were in agreement with literature values.  
The crude acid chloride (1) was added dropwise to a stirred solution of NH4OH 
(80mL of a 25% solution in water, 1180 mmol, 17.2 equiv.) over 25 min at 0 °C. The 
HO OH
O O
Cl Cl
O O
Br Br
1. SOCl2
2.NBS, HBr, CCl4
H2N NH2
O O
Br Br
NH4OH
Scheme 3.3 “2,5-dibromohexaneamide synthesis” 
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reaction was then to stirred at 0 °C for 1 h, after which it was filtered to give an olive-green 
precipitate and a dark filtrate. The precipitate was triturated by suspending in 1:1 
methanol:H2O (80 mL) and heating the mixture at 60°C for 30 min and filtered once more. 
The precipitate was further washed with methanol (80 mL) and dried under vacuum to 
give adequately pure 2,5-dibromoadipic acid diamide, as an off-white powder, and without 
the need for further purification. 
 
1H NMR (500 MHz, DMSO) δ ppm 7.68 (2 H, s, NH2), 7.30 (2 H, s, NH2), 4.29–4.36 (2 
H, m, 2 x CHBr), 1.81–2.06 (4 H, m, CH2CH2). 
 
4E-BP1 Plasmids and Mutagenesis 
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Figure 3.9 “1NMR spectra of 2,5-dibromohexanediamide” 
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Table 3.2 “4E-BP1 Primers” 
 
Human 4E-BP1 plasmid was purchased from Kazusa DNA Research Institute in 
pFN21A HaloTag vector. All primers for cloning and mutagenesis were purchased from 
IDT. The 4E-BP1 insert was transferred from pFN21A to a pMCSG9 vector via LIC cloning 
for amplification of MBP-4E-BP1 plasmid in the DH5α E. coli strain46. Site-directed 
mutagenesis was performed using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent). All DNA sequencing was performed by the University of Michigan DNA 
Sequencing Core. 
 
Protein Expression and Purification 
Expression and purification of activated His-tagged MAPK was done according to 
a protocol and plasmid co-expressing Erk2 and MEK1 obtained by the Forman-Kay Lab 
Primer 
Label Description Sequence 
P1 4E-BP1 LIC Forward 5’ - TACTTCCAATCCAATGCAATGTCCGG – 3’ 
P2 4E-BP1 LIC Reverse 5’ – TTATCCACTTCCAATGTTAAATGTCCATCTCAAAC – 3’ 
P3 C7A mutant Forward 5’- GGGCAGCAGCGCCAGCCAGACCCCAAGC – 3’ 
P4 C7A mutant Reverse 5'- GCTTGGGGTCTGGCTGGCGCTGCTGCCC -3 
P5 C62A mutant Forward 5'- CCTGATGGAGGCTCGGAACTCACCTGTGACCAAAACACC -3' 
P6 C62A mutant Reverse 5'- GGTGTTTTGGTCACAGGTGAGTTCCGAGCCTCCATCAGG -3' 
P7 T37C mutant Forward 5’-CAGCTCCCGCCCGGGGACTACAGCACGTGCCCCGGCGGCACGCTC-3’ 
P8 T37C mutant Reverse 5’ – GAGCGTGCCGCCGGGGCACGTGCTGTAGTCCCCGGGCGGGAGCTG-3’ 
P9 T46C mutant Forward 5'- GGCACGCTCTTCAGCACCTGCCCGGGAG -3' 
P10 T46C mutant Reverse 5'- CTCCCGGGCAGGTGCTGAAGAGCGTGCC -3' 
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from Attila Remenyi at Eo¨tvo¨s Lora´nd University. For unlabeled and 13C15N labeled 4E-
BP1 constructs in pMCSG9, plasmid was transformed into Rosetta cells using a standard 
transformation protocol. Single colonies were picked to inoculate 6 ´ 6 mL overnight 
cultures in either LB media or M9 minimal media containing 50 mg/mL ampicillin (amp) 
that were incubated shaking at 37 °C.  Overnight cultures were used to     inoculate 1 L 
of LB media containing 50 mg/mL amp, and that culture was grown to an OD600 of 0.8. At 
this stage, the culture was induced with 1 mM IPTG and incubated shaking at 37 °C for  
4h. Cells were pelleted by centrifugation at 6000´ g for 15 min at 25 °C, re-suspended in 
Lysis Buffer (6M Guanidium HCl, 50 mM Tris pH 7.5, 500 mM NaCl, 1 mM PMSF, 1 mM 
EDTA, 2 mM DTT), and lysed by sonication. Lysate was then clarified by centrifugation 
at 16,000´ g for 20 min at 4 °C. Clarified lysate was incubated 15 min on Ni-NTA resin in 
a Bio-Rad column, then the flow-through was collected. The Ni-NTA resin was washed 3 
´ with 10 column volumes of Wash Buffer A (6M Guanidium HCl, 50 mM Tris pH 7.5, 200 
mM NaCl, 1 mM EDTA, 2 mM DTT), followed by 3 ´ 10 column volumes washes with 
Wash Buffer B (50 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 2 mM DTT), and eluted 
with Wash Buffer B without Guanidium HCl, and containing a gradient of 0-500 nM 
imidazole. The protein was then concentrated to 5 mL, purified by size-exclusion 
chromatography (SEC), using Storage Buffer (50 mM Sodium Phosphate pH 7.4, 100 mM 
NaCl, 1 mM EDTA, 1 mM DTT) to remove aggregates, and concentrated as needed, with 
concentration monitored by A280. Purified protein was aliquoted, stored at -80°C, and 
aliquots were thawed at 4°C immediate prior to use. 
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Protein 
Construct 
Description 
Isotopic 
Labeling 
Mass 
Expected 
(Da) 
Mass 
Observed 
(Da) 
wt-4E-BP1 wild-type sequence expressed in pFN29K 
vector and cleaved by TEV protease 
N/A 12868 12868 
4E-BP1 
Cys7Dha, 
Cys62Dha 
wild-type sequence expressed in pFN29K 
vector and cleaved by TEV protease, and 
reacted with DBHDA 
N/A 12800 12800 
wt-4E-BP1 wild-type sequence expressed in pMCSG9 
vector and cleaved by TEV protease 
13C15N 13557* 13542 
wt-4E-BP1 wild-type sequence expressed in pMCSG9 
vector and cleaved by TEV protease and 
phosphorylated by MAPK 
13C15N 14022^ 13863, 
13945, 
14021 
4E-BP1 
T37C/T46C 
C7A, C62A, T37C, T46C 4E-BP1 mutant 
expressed in pMCSG9 vector and cleaved by 
TEV protease 
13C15N 13496* 13478 
4E-BP1 
T37Dha/T46Dh
a 
C7A, C62A, T37C, T46C 4E-BP1 mutant 
expressed in pMCSG9 vector, cleaved by TEV 
protease and reacted with DBHDA 
13C15N 13410^ 13410, 
13617 
4E-BP1 T37C C7A, C62A, T37C 4E-BP1 mutant expressed in 
pMCSG9 vector and cleaved by TEV protease 
13C15N 13494* 13478 
4E-BP1 
T37Dha 
C7A, C62A, T37C 4E-BP1 mutant expressed in 
pMCSG9 vector, cleaved by TEV protease and 
reacted with DBHDA 
13C15N 13444^ 13444 
4E-BP1 
T37pCys 
C7A, C62A, T37C 4E-BP1 mutant expressed in 
pMCSG9 vector, cleaved by TEV protease and 
13C15N 13555^ 13557 
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reacted with DBHDA, followed by sodium 
thiophosphate 
*"Mass Expected" assumes 100% isotopic labeling where applicable, it is important to note that isotopic 
labelling of protein is rarely perfectly efficient. 
^"Mass Expected" based on "Mass Observed" in previous step 
Table 3.3 "4E-BP1 Protein Constructs" 
 
4E-BP1 protein kinase phosphorylation  
Wild-type 4E-BP1 was phosphorylated with MAPK using the dialysis technique 
described by Bah and colleagues29. In brief, the phosphorylation reaction was made up 
of 50 ml of 50 mM Tris pH 7.5 at 25 °C, 1 mM EGTA, 2 mM DTT, 20 mM MgCl2 and 
10 mM ATP containing a 5:1 ratio of 4E-BP1:MAPK by molar concentration. The reaction 
was transferred to a dialysis bag placed in 5L of phosphorylation buffer. Phosphorylation 
was allowed to proceed overnight with stirring and completion of phosphorylation being 
monitored by Q-TOF mass spectrometry. 
4E-BP1 chemical phosphorylation 
pCys 4E-BP1 protein was generated as previously described20,32. Briefly, TEV-
cleaved and purified 4E-BP1 was incubated with 1mM fresh DTT for 30 min before buffer 
exchange into Reaction Buffer (6M Guanidinium-HCl, 50mM Sodium Phosphate pH 8.4, 
100mM NaCl, 1mM EDTA). Once in Reaction Buffer, protein was incubated shaking with 
150 equivalents of DBDHA at 37°C for 3h to convert Cys to Dha. Completion of reaction 
was determined by mass spectrometry. The protein was then buffer exchanged into 
Reaction Buffer with the pH adjusted to 7.4. Additions 5000 equivalents of sodium 
thiophosphate pH 8.0 in a solution of 700mg/mL in water were made to the Dha 4E-BP1 
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solution in 10 min increments, with completion of the pCys reaction being monitored by 
Q-TOF mass spectrometry.  
pCys modification of 4E-BP peptide was generated in a similar manner to full-
length protein. Peptide was dissolved in Reaction Buffer. Then incubated shaking with 
150 equivalents of DBDHA at 37°C for 1h to convert Cys to Dha. Completion of reaction 
was determined by mass spectrometry. The reaction was centrifuged at 15,000 xg for 
one minute and the supernatant was transferred to a new tube. Precipitate was washed 
with Reaction Buffer, centrifuged again, and supernatants were pooled. Serial additions 
of 1 μL of a solution of 700mg/mL sodium thiophosphate in water, pH 8.0 in were made 
to the Dha 4E-BP1 peptide solution in 1 min increments, with completion of the pCys 
reaction being monitored by Q-TOF mass spectrometry.  
 
4E-BP Peptide Synthesis 
Peptide 
Label 
Sequence 
Mass 
Expected (Da) 
Mass Observed 
(Da) 
4E-BP1 
Ser65Cys 
RIIYDRKFLMEC(StBu)RN
CPV 
2285.16 2285.16 
4E-BP1 
Ser65Dha 
RIIYDRKFLMEC(StBu)RN
A'PV 
2251.16 2251.16 
4E-BP1 
Ser65pCys 
RIIYDRKFLMECRNpCPV 2275.07 2355.04, 2420.99 
(Figure 5) 
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4E-BP2 
native 
RIIYDRKFLLDRRNSPV 2202.26 2202.27 
4E-BP2 
pSer65 
RIIYDRKFLLDRRNpSPV 2279.21 2282.21 
4E-BP2  
pThr65 
RIIYDRKFLLDRRNpTPV 2293.22 2298.26 
4E-BP2 
Ser65Cys 
RIIYDRKFLLDRRNCPV 2218.24 2218.23 
4E-BP2 
Ser65Dha 
RIIYDRKFLLDRRNA'PV 2184.25 2184.25 
4E-BP2 
Ser65pCys 
RIIYDRKFLLDRRNpCPV 2295.18 2184.24, 2393.27*, 
2330.17 (Figure 6) 
*M+H3PO4, a common adduct in phosphorous containing compounds 
A’ = Dha 
Table 3.4 “4E-BP1 Peptide Sequences” 
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4E-BP peptide sequences were synthesized on a Liberty Blue peptide synthesizer 
on 0.1-mmol scale using Rink Amide resin. All amino acid coupling reactions were 
performed using 5 excess equivalents of Fmoc-AA-OH with 1:1:1 of AA:DIC:Oxyma in 
DMF for 4 min at 90°C for all amino acids.  Fmoc deprotections were performed for 1 min 
at 90°C in 20% piperidine in DMF. All peptides were cleaved from the resin by agitation 
in a 90:0.4:0.4:0.2 by volume solution of TFA:thioanisole:TIPS:H2O for 4 h at 25 °C. The 
cleaved peptide in TFA solution was then precipitated in ice-cold diethyl ether, and the 
precipitate was centrifuged, dissolved, and purified via RP-HPLC. 
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 Protein NMR experiments  
NMR experiments were conducted on Varian INOVA 500 and 600 MHz 
spectrometers, equipped with pulsed-field gradient units, and triple resonance probes, 
and a cryogenically cooled probe. NMR samples contained approximately 0.1mM 15N13C-
labelled protein in NMR Buffer (30 mM Na2HPO4, 100 mM NaCl, 1 mM EDTA, 10% D2O 
Figure 3.10 “Mass Spectrometry Data for Purified 4E-BP2 Peptides” 
 
X = Ser 
X = pSer 
X = pThr 
X = Cys 
R I I Y D R K F L L D R R N X P V 
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v/v, pH 6.0). HSQC experiments were performed at 5°C. NMR data sets were processed 
with the NMRPipe software package47 and analyzed using SPARKY.48  
CD Experiments 
CD samples contained approximately 250 µM peptide in 50 mM Sodium 
Phosphate pH 7.4 and 15% acetonitrile, with or without 50% 2,2,2-trifluoroethanol. CD 
experiments were performed on a Jasco-1500 CD spectropolarimeter with data recorded 
between 260 nm and 190 nm with 5 accumulations per experiment. CD data sets were 
graphed using GraphPad Prism software, and percent helicity of each peptide was 
calculated based on the molar ellipticity minimum at 222 nm as described by Shepherd 
et al.49 Helicity was determined by molar ellipticity of each peptide at 222 nm using the 
equations below.49  
 
Equation 1: 
 
Equation 2: 
 
 
Equation 3: 
 
 
Where,  
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%H = percent a-helix content 
[q]obs222= observed molar ellipticity at 222 nm 
[q]C= Random coil molar ellipticity 
[q]¥222= Infinite  molar a-helix molar ellipticity 
T = temperature in degrees Celsius 
k = finite length correction 
Np = Number of peptide units 
 
Molecular Modeling  
Modeling of 4E-BP phosphoforms were generated from phosphorylated 4E-BP2 
NMR data (PDB: 2MX4) in PyMol software.50 Generation of pSer and pCys were done in 
PyMol using the mutagenesis wizard, builder tool, and PyTMs51 plug-in for PyMol. 
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Chapter 4 – Conclusions  and Future Directions 
4.1. Conclusions 
IDPs  and their conformational transitions are intricately tied to function, allowing 
disordered proteins to play a number of critical roles in normal cell growth and turnover.1-
3 The work described here reveals the enormity of potential for chemical approaches to 
study, dissect, and modulate such transitions. The hypothesis that targeting protein 
conformation and dynamics will directly affect function is supported through examples 
that include studies on the stabilization of regulatory loops in kinases,4 as well as small 
molecule helix stabilization in the case of mitochondrial aldehyde dehydrogenase 
(ALDH2).5 When considering 4E-BPs as a case study, work on stapled peptides carried 
out by my colleagues in the Garner laboratory lay preliminary groundwork for the positive 
impacts of structural stabilization of this protein family.6 Development and discovery of 
small molecules and biologics through in vitro approaches, such as those being 
conducted in our lab, demonstrate the vast opportunity for development of a chemically 
diverse collection of compounds that can be tested in vivo for a deeper understanding of 
how protein disorder functions in cell signaling. 
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4.1.1 On the Use of Conditionally Fluorescent Reporters of Structural Polymorphism in 
IDPs/IDRs 
An exciting outcome of my dissertation research is the development of a 
fluorescent 4E-BP1-based peptide reporter of disorder in the hotspot binding region.7 Its 
amenability to high-throughput screening will undoubtedly lead to the specific discovery 
of secondary structure modulating compounds. While, this approach to high-throughput 
compound discovery has yet to be applied, targeting of the 4E-BP amphipathic helix 
makes an interesting case study on the power of such a method. In addition to the insights 
that will be provided on how chemical perturbation at this axis of cap-dependent 
translation affects cellular metabolism in disease states, 4E-BP based peptides can be 
used to gather in vitro information on ways to infer specificity for peptides with similar 
sequences and modes of action. Of interest, the probing of the thiol-aromatic interaction 
between Phe58 and Cys62 with our peptide reporter has revealed its importance to 4E-
BP1 helix stability. With this knowledge, the unique reactivity of Cys can be utilized to 
confer ligand specificity over both eIF4G and 4E-BP2. The potential for 4E-BP1 specific 
targeting is particularly exciting, as literature suggests that this would be a means of 
inducing tissue specific targeting of cap-dependent translation.8-13  
The information gained through studies of the 4E-BP binding-induced helix will 
provide insights for application of conditionally fluorescent peptide reporter to systems 
beyond induction of a-helicity. Native chemical ligation can be used for the incorporation 
of a fluorophore and quenching thioamide via protein semi-synthesis to probe the 
dynamics of larger protein folds and protein domains.14,15 A relevant example of such a 
fold is the phosphorylation induced 4E-BP b-fold.16 
 105 
4.1.2 On Chemical Mutagenesis as a Route to PTM Mimicry in IDPs/IDRs 
As discussed in Chapter 3, the potential of chemical mutagenesis methodology17-
25 to study post-translational regulation of IDPs is heavily dependent on biological, 
structural, and local environmental contexts of a specific PTM. While pCys appears to be 
a clever, yet simplistically obtained pSer and pThr mimic in over systems, this is not this 
case for 4E-BPs. First, the large radius of the sulfur atom appears to hinder pCys from 
adopting the optimal conformation for b-hairpin induction. In addition, Cys itself is 
extremely disruptive of a-helix.26 In fact that only amino acids with lower helical propensity 
are Pro and deprotonated Glu.26 This significantly complicates the interpretation of data 
suggesting pCys destabilizes the 4E-BP helix, as the sulfur atom itself makes some 
measurable contribution to this observation. Challenges in chemical conversion reactions 
to obtain pCys must also be noted. Even if pCys exhibited the hypothesized structural 
outcomes, difficulty of chemical conversions limit the use of the “tag-and-modify” 
technique by biologists who are best poised to make impactful discoveries through its 
use. Further studies of protein length, sequence, and structure on the efficiency of the 
conversion reactions used to obtain both Dha and pCys will not only yield information on 
what systems made be favorable or unfavorable for “tag-and-modify” methodology, but 
will also provide inspiration for development of new bioorthogonal chemistry for contexts 
deemed unfavorable.   
4.2. Future Directions 
Through my dissertation research, I have taken an interdisciplinary approach to 
explore the structure—function dynamic of IDPs in cellular signaling with two foci: 
conformational regulation of protein disorder and its effect on the PPI of 4E-BPs with 
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eIF4E and PTM mediated regulation of IDP structure and function. While this work 
certainly has implications for chemotherapeutic development in our system and other 
pathways that similarly rely on IDP-mediated regulation, there is still a great deal of work 
to be done on PPI targeting its long-term effects on signaling networks. Specific to 
targeting of cap-dependent translation, many mRNAs that are well-documented to be 
translated in a cap-dependent manner have been found to overcome inhibition of cap-
dependent translation initiation via Internal Ribosomal Entry Site (IRES) units in the 
mRNA transcript.27,28 While the molecular details of how this happen are not yet 
understood, this must be a consideration when targeting the 4E-BP—eIF4E interaction in 
disease states. Additionally, targeting IDPs is an arduous undertaking, and future studies 
must justify the advantages of targeting an IDP over its more ordered binding partners or 
other well-folded proteins in its signaling pathway. 
4.2.1 On Targeting Structural Polymorphism in 4E-BP and Other IDPs 
It will be interesting to see the results of future high-throughput screening efforts 
with the fluorescent peptide reporter that was developed in Chapter 2. A potential 
advantage of structure stabilization as a focus for IDP ligand discovery in cell signaling is 
that it does not explicitly rely on competition with endogenous binding partners. Instead, 
our technique can be viewed as a means of chemically reprogramming a cell and its 
signal transducing components, using a chemical probe to redirect the cell back to a more 
standard mode of functioning. As implied above, obtaining 4E-BP isoform specificity will 
be a major challenge in structural manipulation in this system, considering the high 
sequence homology between the eIF4E-binding sequences of eIF4G and the 4E-BPs.  
There is also the broader question of what chemical libraries for structure inducing ligand 
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discovery will look like. While the dearth of studies on chemical helix stabilization, make 
this question difficult to answer, it does reveal an important research area that medicinal 
chemists and chemical biologists are perfectly primed to elucidate.  
As mentioned above, the combination of native chemical ligation with distance 
dependent thioamide fluorescence quenching is a promising approach to chemical 
probing phosphorylation induced 4E-BP b-fold.14,29,30 There is both biochemical31-35 and 
biophysical16,36 evidence that this fold is critical for inhibition of 4E-BP function and 
stimulation of cap-dependent translation initiation. When considered along with the 
abundance of studies showing the correlation between hyperphosphorylated 4E-BP and 
disease, it can be hypothesized that disruption of the phosphorylation induced fold would 
present a mode of stabilizing the 4E-BP—eIF4E interaction in a way that is resistant to 
the aberrant upstream signaling that drives the increased cap-dependent translation 
observed in cancer and neurological disease models. Finally, it must be stated that while 
ligands discovered in this by this route may modulate structure, the possibility of such 
ligands being biologically inactive cannot be precluded. Thus, functional validation of 
discovered compounds in in vitro binding assays, cell-based assays, and eventually in in 
vivo models will be absolutely necessary for informing structure modulation as a 
biologically relevant method of targeting 4E-BP and other disordered signaling proteins. 
4.2.2 On Chemical and Biological Considerations for the “Tag-and-Modify” Route to PTM 
Mimicry 
Stereospecific phosphomimicry will be a critical consideration for future work on 
chemical mutagenesis for PTM generation. It is possible that this could be achieved, at 
least in part, by templating by the local structural environment, or a conformational 
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restraint at the peptide backbone, as is the case if the target of modification is adjacent 
to a Pro residue. Carbon-carbon bond formation through radical addition to Dha,24 may 
also be able to address this issue if a stereospecific mode of hydrogen introduction at the 
α-carbon is developed. Conditional upon the aforementioned points being holistically 
addressed, chemically accessible PTMs yield immense potential for understanding PTMs 
in the context of protein disorder in a way that does not presently exist. It would certainly 
allow for controlled and intentional dissection of hierarchal PTMs in protein structure, 
protein function, and cell signaling. It could also be adapted for the identification of novel 
PTM mediated IDP binding partners. Finally, identification of novel conformational 
transitions by a chemical phosphomimetic, could be targeted for chemical invention via 
an adaptation of the methodology described in Chapter 2. 
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